CA2431853A1 - Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases - Google Patents
Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases Download PDFInfo
- Publication number
- CA2431853A1 CA2431853A1 CA002431853A CA2431853A CA2431853A1 CA 2431853 A1 CA2431853 A1 CA 2431853A1 CA 002431853 A CA002431853 A CA 002431853A CA 2431853 A CA2431853 A CA 2431853A CA 2431853 A1 CA2431853 A1 CA 2431853A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- mmp
- zinc
- regulator
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Abstract
The present invention relates to MMP regulators that comprise new synthetic peptides, that comprise amino acid sequences structurally similar to those of MMP binding region of TIMPs, coupled to zinc chelators. The invention also relates to methods for making these MMP regulators and their use for the treatment of chronic and acute wounds and for the treatment of angiogenesis-associated diseases.
Description
DESIGN AND USE OF ADVANCED ZINC CHELATING PEPTIDES
TO REGULATE MATRIX METALLOPROTEINASES
FIELD OF THE INVENTION
The present invention relates to compositions and methods for enhancing wound healing, especially chronic wounds (e.g., diabetic wounds, pressure sores). More specifically, the invention relates to improved wound healing through regulation of matrix metalloproteinase activity.
BACKGROUND OF THE INVENTION
In normal tissues, cellular connective tissue synthesis is offset by extracellular matrix degradation, the two opposing effects existing in dynamic equilibrium. Degradation of the matrix is brought about by the action of matrix metalloproteinases (MMPs) released from resident connective tissue cells and invading inflammatory cells.
Normally, these catabolic enzymes are tightly regulated at the level of their synthesis and secretion and also at the level of their extracellular activity. Extracellular control occuxs primarily by regulation with specific enzymes, such as TIMPs (tissue inhibitors of metalloproteinases), which form complexes with MMPs. These complexes prevent MMP action. Cellular level control of MMP activity occurs primarily by regulating MMP gene expression and y down regulating the expression of the membrane bound MMPs (MT-MMP) that activate the excreted proenzyme form of the MMP.
MMPs are a family of neutral metalloenzymes capable of degrading extracellualr matrix (ECM) macromolecules. Members of this family that have been isolated and characterized include interstitial fibroblast collagenase, stromelysin, and type IV collagenase. Other potential members include ~ a poorly characterized 94,000 dalton gelatinase and several low molecular weight gelatinases and telopeptidases. Structurally, MMPs contain a zinc(II) ionic site at the active site of the protein. Binding of zinc to the ionic site is required for hydrOlytlC aCtlvlty.
TIMPs are glycoproteins that specifically regulate interstitial collagenase on a 1:1 stoichiometric basis. That is, TIMPs form very specific regulatory complexes with MMPs, only regulating a specific subset of the MMPs. No naturally occurring TIMP molecule singly regulates all types of MMPs.
In chronic wounds, the ratio of MMPs to TIMPs is high, such that most of the MMPs are unregulated. This unregulated MMP
activity results in the accelerated, uncontrolled breakdown of the ECM, leading to destruction of the newly formed wound bed. Additionally, the concomitant elevation of proteinase levels, cause hydrolyzation of TIMP
molecules, further increasing the MMP to TIMP ratio.
TO REGULATE MATRIX METALLOPROTEINASES
FIELD OF THE INVENTION
The present invention relates to compositions and methods for enhancing wound healing, especially chronic wounds (e.g., diabetic wounds, pressure sores). More specifically, the invention relates to improved wound healing through regulation of matrix metalloproteinase activity.
BACKGROUND OF THE INVENTION
In normal tissues, cellular connective tissue synthesis is offset by extracellular matrix degradation, the two opposing effects existing in dynamic equilibrium. Degradation of the matrix is brought about by the action of matrix metalloproteinases (MMPs) released from resident connective tissue cells and invading inflammatory cells.
Normally, these catabolic enzymes are tightly regulated at the level of their synthesis and secretion and also at the level of their extracellular activity. Extracellular control occuxs primarily by regulation with specific enzymes, such as TIMPs (tissue inhibitors of metalloproteinases), which form complexes with MMPs. These complexes prevent MMP action. Cellular level control of MMP activity occurs primarily by regulating MMP gene expression and y down regulating the expression of the membrane bound MMPs (MT-MMP) that activate the excreted proenzyme form of the MMP.
MMPs are a family of neutral metalloenzymes capable of degrading extracellualr matrix (ECM) macromolecules. Members of this family that have been isolated and characterized include interstitial fibroblast collagenase, stromelysin, and type IV collagenase. Other potential members include ~ a poorly characterized 94,000 dalton gelatinase and several low molecular weight gelatinases and telopeptidases. Structurally, MMPs contain a zinc(II) ionic site at the active site of the protein. Binding of zinc to the ionic site is required for hydrOlytlC aCtlvlty.
TIMPs are glycoproteins that specifically regulate interstitial collagenase on a 1:1 stoichiometric basis. That is, TIMPs form very specific regulatory complexes with MMPs, only regulating a specific subset of the MMPs. No naturally occurring TIMP molecule singly regulates all types of MMPs.
In chronic wounds, the ratio of MMPs to TIMPs is high, such that most of the MMPs are unregulated. This unregulated MMP
activity results in the accelerated, uncontrolled breakdown of the ECM, leading to destruction of the newly formed wound bed. Additionally, the concomitant elevation of proteinase levels, cause hydrolyzation of TIMP
molecules, further increasing the MMP to TIMP ratio.
Many individuals suffer from chronic wounds. Open cutaneous wounds represent one major category of such wounds and include burn wounds, neuropathic ulcers, pressure sores, venous stasis ulcers, and diabetic ulcers. Worldwide, eight million people have chronic leg ulcers and seven million people have pressure sores (Clinica 559, 14-17, 1993). In the U.S. alone, the prevalence of skin ulcers is 4.5 million, including two million pressure sore patients, 900,000 venous ulcer patients and 1.6 million diabetic ulcer patients (Med Pro Month, June 1992, 91-94). The cost involved in treating these wounds is staggering and, at an average of $3,000 per patient, reaches over $13 billion per year for the U.S. alone.
Burn wounds have a reported incidence of 7.8 million cases per year worldwide, 0.~ million of which need hospitalization (Clinica 559). In the U.S., there are 2.5 million burn patients per year, 100,000 of which need hospitalization and 20,000 of which have burns involving more than 20% of the total body surface area (MedPro Month, June 1992).
Many other problems also result from the uncontrolled breakdown of connective tissues by MMPs. These problems include, for example, rheumatoid arthritis; osteoarthritis; osteopenias, such as osteoporosis, periodontitis, gingivitis, corneal epidermal, and gastric ulceration; tumour metastasis, invasion, and growth; neuroinflammatory disorders, including those involving myelin degradation, for example, multiple sclerosis; and angiogenesis dependent diseases, which include angiofibromas, hemangioma, solid tumors, blood-borne tumors, leul~emia, metastasis, telangiectasia, psoriasis, scleroderma, pyogenic granuloma, myocardial angiogenesis, plaque neovascularization, coronary collaterals, ischemic limb angiogenesis, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental.
fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing, peptic ulcer, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, and placentation.
Given the large number of diseases associated with MMP°
activity, there is a need to control MMP activity. Several approaches have been suggested to accomplish such regulation. One approach has focused on the catalytic role of zinc in MMPs, designing zinc-chelating regulators. Potent regulators have been generated by introducing zinc chelating groups, such as peptide hydroxamates and thiol-containing peptides, into substrates. Peptide hydroxamates and TIMPs have been successfully used in animal models to treat cancer and inflammation.
While these hydroxamates are potent at regulators of MMPs by binding to zinc, they are toxic to humans because they bind to all zinc-containing enzymes. Because many biochemical reactions occurring in the body require zinc, use of the hydroxamates detrimentally effects these other functions and can result in death.
Burn wounds have a reported incidence of 7.8 million cases per year worldwide, 0.~ million of which need hospitalization (Clinica 559). In the U.S., there are 2.5 million burn patients per year, 100,000 of which need hospitalization and 20,000 of which have burns involving more than 20% of the total body surface area (MedPro Month, June 1992).
Many other problems also result from the uncontrolled breakdown of connective tissues by MMPs. These problems include, for example, rheumatoid arthritis; osteoarthritis; osteopenias, such as osteoporosis, periodontitis, gingivitis, corneal epidermal, and gastric ulceration; tumour metastasis, invasion, and growth; neuroinflammatory disorders, including those involving myelin degradation, for example, multiple sclerosis; and angiogenesis dependent diseases, which include angiofibromas, hemangioma, solid tumors, blood-borne tumors, leul~emia, metastasis, telangiectasia, psoriasis, scleroderma, pyogenic granuloma, myocardial angiogenesis, plaque neovascularization, coronary collaterals, ischemic limb angiogenesis, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental.
fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing, peptic ulcer, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, and placentation.
Given the large number of diseases associated with MMP°
activity, there is a need to control MMP activity. Several approaches have been suggested to accomplish such regulation. One approach has focused on the catalytic role of zinc in MMPs, designing zinc-chelating regulators. Potent regulators have been generated by introducing zinc chelating groups, such as peptide hydroxamates and thiol-containing peptides, into substrates. Peptide hydroxamates and TIMPs have been successfully used in animal models to treat cancer and inflammation.
While these hydroxamates are potent at regulators of MMPs by binding to zinc, they are toxic to humans because they bind to all zinc-containing enzymes. Because many biochemical reactions occurring in the body require zinc, use of the hydroxamates detrimentally effects these other functions and can result in death.
Other known zinc-chelating MMP regulators are peptide derivatives based on naturally occurring amino acids and are analogues of the cleavage site in the collagen molecule (Odake et al. (1994) Biophys. Res. Comm. 199, 1442-46). Some MMP regulators are less peptidic in structure and may more properly be viewed as pseudopeptides or peptide mimetics. Such compounds usually have a functional group capable of binding to the zinc (II) bound in the MMP.
Known compounds include those in which the zinc binding group is a hydroxamic acid, carboxylic acid, sulphydryl, or oxygenated phosphorus (for example, phosphinic acid and phosphonamidate, including aminophosphonic acid) groups.
Other approaches include small molecule regulation (Levy et al. (1998) J. Med. Chem. 41, 199-223; Wojtowicz-Pragaet al. (1997) Invest. New Drugs 15, 61-75; Duivenvoorden, et al. ( 1997) Invasion and Metas. 17, 312-22) and regulation via anti-MMP antibodies (Su et al.
(1995) Hybridoma. 14, 383-90). ' More specifically, an elastase inhibitor is disclosed in U.S.
Patent No. 5,734,014 to Ishima et al. Elastase secreted by neutrophils causes tissue damage, and in this process, creates an active abundance of oxygen. Elafm isolated from psoriatics has elastase inhibiting activity.
However, this naturally occurring elafin is unstable to oxidation. Ishima developed elafin derivatives that are stable to oxidation so that elastase regulation can be more efficient. The oxidation-stable derivative is created by partly modifying the amino acid sequence of natural elafm.
The modification can be created by either chemical synthesis or site-directed mutagenesis.
U.S. Patent No. 5,464,822 to Christophers et al. discloses a polypeptide that possesses inhibitory activity against human leukocyte elastase. ' The polypeptides possess inhibitory activity that is specific for serine proteases. For example, they possess inhibitory activity against proteases, such as human leukocyte elastase and porcine pancreatic elastase, but do not possess any significant inhibitory activity against trypsin. These polypeptides can be prepared by genetic engineering or obtained from psoriatic scales of human skin.
U.S. Patent No. 5,698,671 to Stetler-Stevenson et al.
discloses a protein defined by the presence of specific cysteine-containing amino acid sequences, isolated from the conditioned media of cultured human tumor cells, that binds with high affinity to MMPs and analogs thereof. The particular inhibitor is made by preparing peptides and proteins having a cysteine residue at the same interval as that of the various tissue inhibitors of metalloproteinase (TIMPs). The peptides must have at least two appropriately spaced cysteines to ensure inhibitory activity by virtue of a disulfide bridge formation. In addition, the invention discloses a method for purifying natural MMP inhibitors by MMP affinity chromatography.
Known compounds include those in which the zinc binding group is a hydroxamic acid, carboxylic acid, sulphydryl, or oxygenated phosphorus (for example, phosphinic acid and phosphonamidate, including aminophosphonic acid) groups.
Other approaches include small molecule regulation (Levy et al. (1998) J. Med. Chem. 41, 199-223; Wojtowicz-Pragaet al. (1997) Invest. New Drugs 15, 61-75; Duivenvoorden, et al. ( 1997) Invasion and Metas. 17, 312-22) and regulation via anti-MMP antibodies (Su et al.
(1995) Hybridoma. 14, 383-90). ' More specifically, an elastase inhibitor is disclosed in U.S.
Patent No. 5,734,014 to Ishima et al. Elastase secreted by neutrophils causes tissue damage, and in this process, creates an active abundance of oxygen. Elafm isolated from psoriatics has elastase inhibiting activity.
However, this naturally occurring elafin is unstable to oxidation. Ishima developed elafin derivatives that are stable to oxidation so that elastase regulation can be more efficient. The oxidation-stable derivative is created by partly modifying the amino acid sequence of natural elafm.
The modification can be created by either chemical synthesis or site-directed mutagenesis.
U.S. Patent No. 5,464,822 to Christophers et al. discloses a polypeptide that possesses inhibitory activity against human leukocyte elastase. ' The polypeptides possess inhibitory activity that is specific for serine proteases. For example, they possess inhibitory activity against proteases, such as human leukocyte elastase and porcine pancreatic elastase, but do not possess any significant inhibitory activity against trypsin. These polypeptides can be prepared by genetic engineering or obtained from psoriatic scales of human skin.
U.S. Patent No. 5,698,671 to Stetler-Stevenson et al.
discloses a protein defined by the presence of specific cysteine-containing amino acid sequences, isolated from the conditioned media of cultured human tumor cells, that binds with high affinity to MMPs and analogs thereof. The particular inhibitor is made by preparing peptides and proteins having a cysteine residue at the same interval as that of the various tissue inhibitors of metalloproteinase (TIMPs). The peptides must have at least two appropriately spaced cysteines to ensure inhibitory activity by virtue of a disulfide bridge formation. In addition, the invention discloses a method for purifying natural MMP inhibitors by MMP affinity chromatography.
Despite these varied approaches, the current art does not selectively regulate MMP activity. Traditionally, high affinity regulators.
have been utilized, resulting in complete MMP inhibition. However, shutting off all MMP activity is actually deleterious to the healing process, as some MMP activity is required for tissue remodelling. For example, potent inhibition aimed at binding the zinc (II) site is toxic to humans because it shuts off bind to all zinc-containing enzymes. It is therefore necessary to have regulation be selective.
Thus, there is a need in the art for improved regulation of MMPs to promote healing of chronic and acute wounds.
There is also a need in the art for an inhibitor having relatively good affinity, which is selective.
Furthermore, there is a need in the art for MMP inhibitors that are not toxic to the individual to whom they are adminisered.
SUMMARY OF THE INVENTION
Using a novel approach to wound site proteinase management, the present invention, in one aspect, provides a new class of MMP regulators. These regulators comprise a zinc chelator covalently attached to a peptide that corresponds to a region of a TIMP
protein that directly interacts with an MMP molecule in the vicinity of the catalytic zinc molecule to bind wound site proteinases. The binding specificity of the peptide will bring the zinc chelator into molecular proximity of the MMP bound zinc in such a way as to allow ligation. In addition to this affinity, the exact sequence of the peptide will allow targeting of specific MMPs. This chemistry regulates the level of MMP
activity to a point that promotes healing. This provides a MMP regulator which can, with high affinity, selectively regulate MMP activity unlike known MMP regulators.
In another aspect, the present invention provides a method for making the new class of MMP regulators. The method comprises binding a zinc chelator to synthetic peptides. The peptide sequences chosen were the part of the TIMP that made the closest approach to the MMP n the vicinity of the catalytic zinc. The sequence is a common structural feature of the binding interface.
In yet another aspect, the present invention provides methods of treating chronic and/or acute skin wounds and other diseases in which MMPs play a role. These methods are advantageous over conventional methods in that they provide both improved selectivity and improved affinity. Additionally, the methods of the present invention provide selective binding to MMPs without causing potential harm to the individual being treated. This is accomplished through the use of novel MMP regulators including a zinc chelator attached to a TIMP derived peptide. These compositions are particularly effective at bind MMP
without compromising other zinc-dependent biochemical activities.
Finally, by applying these novel MMP regulators to an area to be treated, the present invention provides a method of controlling diseases cause by uncontrolled MMP activity without the use of toxic inhibitors.
Therefore, it is an object of the invention to provide new MMP regulators.
It is another object of the invention to provide MMP
regulators that comprises a zinc chelator and synthetic peptides containing novel amino acid sequences that bind to the TIMP binding region of the MMP.
It is yet another object of the invention to provide novel synthetic peptides for use in the production of the MMP regulators of the invention.
It is a further object of the present invention to provide a novel zinc chelator for use in the production of the MMP regulators of the invention.
It is an obj ect of the invention to provide synthetic peptides having SEQ ID Nos. 1, 2, and 3.
It is another object of the present invention to provide MMP
regulators comprising peptides having SEQ ID Nos. 1, 2, or 3 and a zinc chelator.
It is yet another object of the invention to provide methods for treating chronic and acute wounds.
It is a further object of the present invention to provide methods for treating angiogenic-associated diseases.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates a time course reaction of MMP-9 hydrolysis of fluoresceinated collagen in the presence of increasing amounts of the zinc chelating peptide. The curves (from top to bottom) represent MMP-9:ChePep-1 molar stoichiometries of 1:0, 1:0.25, 1:0.5, and 1:1. ChePep-1 is composed of PSDE coupled with the peptide having SEQ ID No. 4. The graph shows fluorescence as a function of time in the continuous assay.
Figure 2 depicts ChePep-2 regulation of MMP-9 via FRET
assay. ChePep-2 is composed of IDA coupled with a peptide having Seq ID No. 5. This mixture was added to the FRET substrate peptide in reaction buffer. Fluorescence measurements were made at the indicated times. The curves represent ChePep-2: MMP-9 molar stoichiometries of 0:1 (closed circles), 0.1:1 (open circles), 0.2:1 (closed squares), 0.3;1 (open squares).
Figure 3 represents ChePep-3 (closed squares) and ChePep-4 (open circles) regulation of MMP-9 via FRET assay. ChePep-3 is made by combining PSDE with a peptide having SEQ ID No. 6 and ChePep-4 is made by combining IDA with a peptide having SEQ ID No.
6. ChePeps were incubated with MMP-9 for 10 minutes to effect binding. This mixture was added to the FRET substrate peptide in reaction buffer. Fluorescence measurements were made at the indicated times. MMP-9 only control is shown for reference (closed circles).
ChePep:MMP-9 molar stoichiometry is 0.25:1.
Figure 4 illustrates ChePep-5 regulation of MMP-9 via FRET assay. ChePep-5 is composed of a AFTA combined with a peptide having SEQ ID No. 7. ChePep-5 was incubated with MMP-9 for 10 minutes to effect binding. This mixture was added to the FRET
substrate peptide in reaction buffer. Fluorescence measurements were made at the indicated times. The curves represent ChepPep-5: MMP-9 molar stoichiometries of 0:1 (closed circles), 0.1:1 (open circles), 0.2:1 (closed squares), 0.3:1 (open squares). Excitation was at 365 nm, and the emission was fixed at 450 nm.
Figure 5 shows ChePep-6 regulation of MMP-9 via the FRET assay. ChePep-6 is made by combining AFTA with a peptide having SEQ ID No. ~. ChePep-6 was incubated with MMP-9 for 10 minutes to effect binding. This mixture was added to the FRET
substrate peptide in reaction buffer. Fluorescence measurements (Excitation 365 nm, Emission450.nm) were made at the indicated times.
The curves represent ChepPep-6: MMP-9 molar stoichiometries of 0:1 (closed circles), 0.1:1 (open circles).
Figure 6 depicts SPR analysis of ChePep-6 binding to immobilized MMP-9 that is on the surface of a BiaCore CM-5 chip. The sensogram shows the relative SPR signal as a function of time for a 400 second association phase and an 800 second dissociation phase. Flow rate was maintained at a rate of 20 ~.L per minute.
Figure 7 represents compound viability assays. The graph plots the percent viability of the peptides utilized in this study relative to a PBS control. Error bars are +/-SD. Samples (left to right) are as follows: PBS positive control, 1%Triton X-100 negative control, ChePep-1, ChePep-2, ChePep-3, ChePep-4, ChePep-5, and ChePep-6.
Figure 8 is a reaction scheme for modification of EDTA to PSDE to allow coupling of the EDTA chelator to the peptides of the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
MMPs contain a zinc molecule located in the active site.
This zinc molecule intimately participates in the chemistry of degrading collagen. As a result, if the zinc is blocked or removed, enzymatic activity of the MMP can be inhibited. The present invention provides compositions (referred to herein as ChePeps) for the regulation of MMP
activity. These compositions comprise a zinc chelator that is covalently attached to a TIMP-derived peptide. The zinc chelator is any compound that binds zinc, whether or not the molecule is a true chelator. The TIMP-derived peptide corresponds to a region of the TIMP protein that directly interacts with the MMP molecule in the vicinity of the catalytic zinc molecule. The binding specificity of this peptide assists in bringing the zinc chelator into molecular proximity with the MMP bound zinc in such a way as to allow ligation of the zinc from the MMP. In addition to this affinity, the exact sequence of the peptide will allow targeting of specific MMPs. This chemistry regulates the level of MMP activity to a point that promotes healing.
Preferably, modern molecular modeling methodologies are employed to design the novel peptides of the present invention that can bind to the zinc (II) site of MMPs and, therefore, regulate a broad range of MMPs. Analysis of the three-dimensional structure of the various MMPs and TIMPs, and . the chemical nature and identification of conserved and variant amino acids in the MMP-TIMP contact interface, is preferably accomplished through molecular modeling utilizing two visualization programs, Swiss PDB Viewer (Guex and Peitsch, 1997) and Rasmol (Sayle and Milner-White, 1995). The present inventors.
have found through visualization of TIMP~MMP complexes that the TIMP molecules make significant contact with the area surrounding the MMP active site.
Other investigators have explored the interaction between MMPs and TIMPs. (Butler et al. (1999) J. Biol. Chem. 274, 20391-96;
Overall et al. (1999) J. Biol. Chem. 274, 4421-29; Menget al. (1999) J.
Biol. Chem. 274, 10184-89). In one embodiment, the present invention comprises derivation of peptides from TIMP proteins that comprise structures in accordance with the three regions of the TIMP proteins that are in close proximity to the MMP catalytic zinc.
In another embodiment, the novel synthetic peptides of the present invention comprise relatively short stretches of amino acids that correspond to the TIMP/MMP binding domain. These peptides can be coupled to a zinc chelator and are capable of binding many MMP
enzymes in the region of the catalytic zinc.
In a preferred embodiment, the present invention comprises thr ee peptides derived from TIMP regions that have a large number of specific side chain interactions with MMPs. The exact sequence of the peptide employed allows targeting of specific MMPs. These sequences are derived from three separate regions of TIMPs I-IV that contact MMPs.
These preferred peptides comprise the amino acid sequences designated as SEQ ID Nos. 1-3. These sequences are shown in Table 1 below. The peptide having SEQ ID No. 1 spans MMP amino' acids 2-9. These peptides are seven amino acids in length. The peptide having SEQ ID No. 2 spans MMP amino acids 62-73 and is 12 amino acids in length. The peptide having SEQ ID No. 3 is 9 amino acids in length encompasses MMP residues 97-105.
Within these preferred peptides, there is a large degree of sequence variation, as denoted by positions in parentheses. This variability can be used as a tool to modulate binding affinity and specificity of TIMP binding interactions. The exact sequence of the:
peptide can be altered to modulate binding affinity and/or specificity, so long as there is a single cysteine residue in the peptide. These three preferred peptides can be further modified by C-ter amidation and N-ter acetylation. This charge neutralization is often found to increase binding affinity as it mimics the peptide being in the context of a whole protein.
In sum, these specific peptides allow for altering the level of specific MMPs in a coordinated manner.
Table 1. Peptide Family Sequences SEQ ID No. C-(S/T)-C-(S/A/V)-P-H-P
SEQ ID No. (I/V)-(E/Q/R)-(F/Y)-(I/V)-(Y/H)-T-(A/P/E)-(P/F/A)-(S/D/M)-(A/S)-(V/L)-(C/G) SEQ ID No. (M/V/L)-(H/F/Y)-(I/T)-(T/H/G)-(L/T)-C-(D/N/S)-(F/Y)-(I/V) While not wishing to be bound by the following theory, it appears that the preferred ChePep complexes block the imino carboxylate groups via zinc chelation prior to activating the remaining carboxyl group for coupling to the peptides. Once liganded to the zinc ion, these carboxyl groups are not able to participate in the activation reaction. The zinc binding affinity is high enough to ensure a slow off rate, so that the liganding carboxyls are bound to the zinc throughout the NHS/EDC reaction. (See examples) The zinc ion is then removed by extensive dialysis. For example, the material can be dialyzed through a 500 MWCO cellulose acetate dialysis tube against 50% phosphate buffered saline (PBS)/water, preferably at room temperature for 48 hours.
In a preferred embodiment, the zinc chelator is a molecule that contains a diacetic acid moiety and ,thus, a good chelator of certain divalent cations, including zinc. Although these compounds are preferred, any small organic molecule that has the ability to ligand or, chelate a zinc molecule can sterically access the MMP active site (without making any deleterious electrostatic interactions) is capable of incorporation into a chelating peptide (ChePep). The chelation process itself is not specific, in that any zinc is potentially a chelation target.
Possible chelators include, but are not limited to, EDTA, EGTA, DTPA, CDTA, HEDTA, NTA, citric acid, salicylic acid, and malic acid. Other chelators include peptides that can bind zinc. For example, peptides SEQ ID No. 9 (CDIC) or SEQ ID No. 10 (HTITH) chelate the zinc moiety through interactions with the two cysteines (SEQ ID No. 9) or the two histidines (SEQ ID No. 10). These sequences are derived from the consensus structure of the zinc finger motif described by Berg (Berg et al., Ann Rev Biophys Biomol Struct, 1997, 26: 357-71. These peptides can be coupled to the targeting peptide via standard peptide synthesis.
In a preferred embodiment, one of three zinc chelating molecules is covalently attached to one of the several TIMP derived peptides that comprise the present invention. The chemical structures of.
these three zinc chelating molecules: pyridine disulfide ethylenediaminetetraacetic acid (PSDE), amino-iminodiacetic acid (IDA), and 2-amino-4-fluorophenol N,N, O triacetic acid (AFTA), are depicted below in Structure 1.
Structure 1 ooc~rr ~N ~~N
H
ooC~N
PSDE
oOC
ooc~N ooc' AFTA
Pyridine disulfide ethylenediaminetetraacetic acid (PSDE) of the present invention is produced in a literature synthesis. (Hayward et al (1995), J. Org. Chem. 60, 3924-27) Covalent coupling of PDSE to the peptide is carried out by a simple stoichiometric disulfide exchange with a cysteine at the amino terminus. Typically the process results in a.
substantially pure product with an overall yield of about 10-25 percent.
The peptide sequence shown in Structure 2 below is a modification of SEQ ID No. 1 wherein the cysteine in position 3 is replaced with an alanine. This molecule can be directly coupled to any free thiol via a simple disulfide exchange reaction.
Structure 2 ooc s~
o s I
ooC~N ~ H~
~N
OOC~ N I I
OOC
Peptide sequences: C
C(T/S)X(S/V/A)P(P/V/S/A)H
In another embodiment, the present invention provides PSDE be coupled to SEQ ID No. 4 (CSAVPVH) with an overall yield of 80 percent. The reaction product is then purified via RP-HPLC as described in the Example. Introduction of this molecule, ChePep-l, to MMP-9 prevents the enzyme from degrading fluoresceinated collagen in a dose dependent manner as is shown in Figure 1.
In yet another embodiment, the present invention provides creation of a combined regulator (binding specificity via the peptide and zinc chelation via the small molecule) by covalently joining EDTA or IDA to a TIMP derived peptide sequence. Ethylenediaminetetraacetic acid (EDTA) and iminodiacetic acid (IDA) are potent chelators of zinc.
However, an EDTA chelator needs some prior literature synthesis in order to perform a coupling reaction preferred by the present invention.
This synthesis is described by Hayward et al. (J. Org. Chem., Vol 60(12), 1995, 3924-3927) and is presented in Figure 8. Such synthesis is not required for IDA because it is relatively easy to couple IDA to the carboxylate group of an aspartate that has been converted into a~
succinimide ester upon reaction with N-hydroxysuccinimide (NHS)/ N-ethyl-N'-(dimethylaminopropyl)carbo-diimide (EDC) (EDC/NHS).
By coupling IDA to a similar peptide, SEQ ID No. 5 (DSAVPVH), the effect of the size of the EDTA moiety on ChePep-1 (PSDE and SEQ ID No.4) can be determined. In this instance, the carboxylate group of the N-ter peptide aspartic acid is activated to a succinimide ester via incubation with EDC/NHS. This straightforward reaction is commonly used to link free amino groups with activated carboxylates. The general structure of a peptide that is covalently coupled to IDA through an activated aspartic acid carboxylate is shown below in Structure 3.
Structure 3 0OC\
00c~rI1 Peptide Sequences:
D (T/S) X (S/V/A) P (P/V/S/A) H
HN O
O=C
CHZ
H2N- ~ H-C-~- U U
Preferably, the entire synthetic scheme that couples IDA to the peptide and purifies the final product proceeds with an overall 49, percent yield. To avoid possible contaminants in the reaction, use a peptide with a C-ter amide group. Hence the only free carboxyl group in the peptide should be the aspartic acid sidechain.
The molecule ChePep-2 (IDA and SEA ID No. 5) regulates.
MMP-9 in the fluorescence resonance energy transfer (FRET) assay in a dose dependent manner. The construct is significantly more effective in regulating MMP-9 than was ChepPep-1, as demonstrated in Figure 2.
This may be due to the ability of an IDA moiety to more effectively ligate the active site zinc than PSDE because of stearic considerations as well as the need to satisfy charge interactions with the second chelating group on PSDE. In addition, the neutralization of the C-ter negative charge on the peptide via the amidation may also alter binding affinity.
In another embodiment, PSDE is coupled to a peptide of SEQ ID No. 2. Specifically, PSDE is coupled to a peptide having SEQ
ID No. 10 that is aminated at the amino terminus (IYTACMSAV-NH2) via the same disulfide exchange reaction previously discussed. The yield for the final product was 37%. The generalized structure of a chelating peptide (ChePep) composed of PSDE and SEQ ID No. 2 is shown below.
Structure 4 ooc ooC~N ~ HZ
N
a oOC~N O 6 00cJ
Peptide Sequences:
(I/V) (Y/I~ T (P/A/E) C (S/M/D) (E/S) (S/A) (V/L) If the cysteine residue in the fifth position of the above molecule is altered to aspartic acid, then IDA can be incorporated into the structure at the same position. In a preferred embodiment, IDA is coupled to SEQ ID No. 2, specifically, the peptide of SEQ ID No. 11 via the EDC/NHS reaction described in the Examples section. The final product yield was 75 percent. RP-HPLC chromatograms of both ChePep molecules revealed a single 214 nm absorbing peak.
Both ChePep-3 (PSDE and SEQ ID No. 6) and ChePep-4 (IDA and SEQ ID No. 6) show nearly identical ability to regulate MMP=
9 in the standard FRET assay. The time dependent regulation course is displayed in Figure 3. Despite the fact that there are differences between IDA and PSDE, molecular modeling indicates that the chelating groups of both ChePep constructs have similar accessibility to the MMP active, site zinc. In fact, the second chelating group of PSDE does not make any energetically unfavorable interactions that would lower binding affinity. It is believed that ChePep-3 may gain some binding energy by the interaction of the carboxylate oxygen on the free liganding moiety with a MMP-9 backbone amide.
Molecules like 2-amino-4-fluorophenolN,N, 0 triacetic acid (AFTA) are not, according to scientific literature, generally known or used as metal chelators, but can in fact readily chelate zinc in this application. AFTA is found to bind well into the active site of MMP-like enzymes. The diacetate group off the 2 ring position chelates the Z111C. The third acetate group can be used to couple a peptide to the molecule. The electronegative fluorine may also contribute to MMP
regulation by making specific interactions in the enzyme active site. The general structure of SEQ ID No. 3 covalently linked to AFTA is depicted below.
Structure 5 F
O
O~HN 2 3 N
COO COO
Peptide sequences:
C(T/S)x(S/V/A)P(P/V/S/A)H C . ~~ I-The above structure is created by coupling a peptide having SEQ ID No. 7 (VHTHLCD) to an AFTA zinc chelator using the same EDCMS chemistry previously described, except that the activated carboxyl group was donated by the AFTA moiety. Since there are three free carboxyl groups found on AFTA, only two of which can participate in zinc ligation (see Structure 1 ), it is necessary to make those chelating groups unreactive to EDC/NHS treatment. This can be accomplished by mixing AFTA with zinc sulfate prior to EDC/NHS activation. The zinc ion is chelated by the iminodiacetic acid moiety, leaving a single free carboxylate. The succinimide ester is then formed on this group as described in the Examples section. The activated AFTA-zinc complex is coupled to the N-ter amino group of the peptide, and the resulting molecule (ChePep-5) is purified to homogeneity by RP-Phase HPLC., Preferably, the total recovery yield was 61 % and the final material is judged to be 97% pure. The generalized structure of this type of regulator, shown in Structure 5, is capable of preventing the hydrolysis of the FRET peptide in a dose dependent manner.
In fact, according to the molar stoichiometries test depicted in Figure 4, ChePep-5 proves to be a better regulator than the TDA or the PSDE based chelating peptides. Its success can be attributed to, but not limited to, four factors: the fluorine group which, because of its electron negativity, tenaciously binds to proteins; the ring itself, being hydrophobic, binds well to the hydrophobic active site of the MMP; the presence of three carboxyl groups to bind to allow for zinc chelation;
and the amino groups to create specificity.
In another embodiment of this invention, a second AFTA
peptide construct is synthesized. This peptide (ChePep-6) comprises SEQ ID No. ~ (CTCVP) and an AFTA, with the AFTA molecule coupled to the peptide amino terminus. Coupling is preferably performed by first mixing an equal amount of zinc sulfate and AFTA.
The resulting complex is then activated with NHS/EDC. An amide coupling is then performed using the N-ter region of the peptide.
Alternatively, AFTA can be linked to the cysteine thiol via a disulfide exchange reaction. The structure of the preferred chelating peptide is shown in Structure 6 below.
Structure 6 This chelating peptide possesses the ability to prevent the hydrolysis of the FRET substrate peptide in the standard assay. As seen in Figure 5, ChePep-6 is an effective MMP-9 regulator at low molar stoichiometries.
In addition, ChePep-6 binds quickly and with high affinity; and once bound, ChePep-6 does not dissociate as seen in Figure 6. In fact, the combination of a group I peptide and an AFTA moiety resulted in the most potent regulator of all the ChePeps.
In another aspect, the present invention comprises the treatment of chronic and acute wounds. By applying the composition to the chronic wound, MMP activity can be regulated. Specifically, the composition comprises a peptide with binding specificity to bring the zinc chelator into molecular proximity of the MMP bound zinc in such a way as to allow ligation. In addition to this affinity, the exact sequence of the peptide will allow targeting of specific MMPs. This chemistry regulates the level of MMP activity to a point that promotes healing.
A highlight of this peptide based therapy is the plasticity in which this material can be applied to a chronic wound. Where the infection is localized to the skin, a preferred formulation is an ointment, lotion or other topical formulation. The composition for topical application useful in the present invention can be made into a variety of product types. These include, but are not limited to, creams, gels, sticks,.
sprays, pastes, mousses, or any aqueous medium. These product types can comprise several types of carrier systems including, but not limited to, solutions, dispersions, emulsions, gels, solids, and liposomes.
Additionally, the peptides can be introduced into the wound bed in a continuous manner via delivery by the wound bandage material itself.
Preferred dose ranges for treatment of chronic wounds are between approximately 0.01 and 1.0 mg/mL
Finally, another embodiment of the present invention is to~
control specific MMP activity. Certain diseases are caused by uncontrollable MMP activity. In fact, some diseases are caused by only a certain of the nine MMP molecules. By designing peptides that correspond with a specific MMP's active site, and then combining a zinc chelator to the peptide, only targeted MMP activity is regulated with a high degree of affinity and specificity.
The present invention is non-toxic in a skin equivalent model. The generally toxic effects of a non-specific zinc chelator are.
mitigated by the fact that the peptide portion of the ChePep construct directly targets the construct to the MMP active site in such a way as to minimize chelation at secondary (non MMP) targets.
The present invention is further illustrated and supported by the following examples. However, these examples should in no way be considered to further limit the scope of the invention. To the contrary, one having ordinary skill in the art would readily understand that there are other embodiments, modifications, and equivalents of the present invention without departing from the spirit of the present invention and/or the scope of the appended claims.
BASIC PROCEDURES
All peptides were synthesized by Sigma-Genosys, Inc.
using conventional techniques. The released peptides were purified to >95% homogeneity via RP-HPLC by the company. The pooled eluted peak material was desalted and lyophilized. Mass Spec analysis confirmed the peptide molecular weight and purity. Unless otherwise noted, all chemicals were purchased from Sigma Chemical Corp. or from Fluka Chemical Co. Active MMP-9 enzyme Was 'purchased from Calbiochem.
Molecular modeling utilized two visualization programs, Swiss PDB Viewer (Guex and Peitsch, 1997) and Rasmol (Sayle and Milner-White, 1995). Model work was performed on a Compaq PC
running Windows 95, as well as a Silicon Graphics, Inc. Octane UNIX
workstation. Additionally, the Cerius2 molecular package from Molecular Simulations, Inc. was utilized on the Octane. Three dimensional structure files were downloaded from the Protein Databank as follows (filename, reference): MMP-1 (1FBL, Li et al., 1995), MMP-2 (1GEN, Libson et al., 1995), MMP-8 (1JA0, 1JAN, Grams, et al., 1995; Reinemer et al., 1994), MMP-9 (1MM~, Browner et al., 1995), TIMP-2/MT-1 MMP complex (1BUV, Fernandez-Catalan et al., 1998), TIMP-2 ( 1 BR9, Tuuttila et al., 1998), and TIMP-1 /MMP complex (lUEA, Gomis-Ruth et al., 1997; Huang et al., 1996; Becker et al., 1995). These files were used to analyze the three-dimensional structure 2~
of the proteins, and the chemical nature and identification of conserved and variant amino acids in the MMP-TIMP contact interface. This information was utilized to design a minimalist peptide that could be coupled to a zinc chelator that would bind many MMP enzymes in the region of the catalytic zinc.
EXAMPLE 1. IDA Chelatin~ Peptides Peptide was resuspended in water to a final concentration of 100 mM. The amino form of IDA was dissolved in a small amount of DMSO followed by the slow addition of water until the compound was at a concentration of 150 mM. To the IDA solution was added N-.
hydroxysuccinimide (NHS), to a final concentration of 175 mM and N-ethyl-N'-(dimethylaminopropyl)-carbodiimide (EDC) to a final concentration of 400 mM. The solution was incubated at 37 °C with gentle stirring for 30 minutes. The previously prepared peptide solution was added to this reaction slowly over a period of 5 minutes. Stirring continued for an additional 30 minutes. The reaction was quenched by the addition of ethanolamine-HCl to a final concentration of 1.0 M. The final mixture was taken to dryness in a rotovac over a period of 10 hours.
The solid material was then resuspended in 500 p,L of water and the chelating peptide was purified away from unreacted species via RP-HPLC. A 250 mm x 100 mm, 5 ml Hypersil ODS-2 RP column was chromatographed with a mobile phase of A: 0.1 % TFA/water, B: 0.1 TFA/acetronitrile. After sample injection, a gradient of 100%A (0 to 2 min) and 0-60% B (2 to 25 min) was applied. The chelating peptide was detected at 214 nm and was 96% pure by peak integration. The eluting peaks were pooled, mixed with 3 volumes of water, and lyophilized.
The resulting powder was resuspended in water and dialyzed through a 500 MWCO cellulose acetate dialysis tube versus 50% phosphate buffered saline (PBS)/water. Chelating peptide was aliquoted and stored frozen at -20 °C.
Example 2. AFTA Chelating Peptides AFTA (50 mg) was dissolved in a small amount of DMSO
followed by the slow addition of water until the compound was at a concentration of 200 mM. To this solution was added zinc sulfate to a final concentration of 300 mM. This solution was stirred slowly at room temperature for 1 S minutes. The sample was then treated with EDC/NHS as described in Example 1. The resulting AFTA-succinamide ester was coupled with a peptide having SEQ ID No. 7 or 8, and the resulting peptide was purified as discussed in Example 1. After lyophilization, the AFTA-peptide was resuspended in water, and it was extensively dialyzed versus water in a 500 MWCO cellulose acetate dialysis tube. The absence of zinc ion was confirmed by atomic absorption spectroscopy.
Example 3. PSDE Chelating Peptides PSDE was prepared according to the method of Hayward et al (1995). This material was coupled directly to a stoichiometric amount of a cysteine containing peptide having SEQ ID No. 4 or 6 by the following disulfide exchange reaction. PSDE in an amount of 100 mM
in water and peptide in an amount of 100 mM in 25 mM Tris-HCl (pH' 7.2) were mixed and allowed to react for 45 minutes at 30 °C. The product was purified from the reactants by dialysis versus 10 mM Tris-HCl (pH 7.2) in a 500 MWCO cellulose acetate dialysis tube. The product was further purified by RP-HPLC as described in Example 1.
Example 4. Regulation of MMPs Two enzymatic assays were performed. The first assay measured the enzymatic hydrolysis of fluoresceinated collagen by MMP-9 as a function of time. Fluoresceinated collagen (Molecular Probes, Inc.), at a concentration of 5 ~.M was added to reaction buffer (50 mM Tris-HCl (pH 7.6), 150 mM NaCI, 5 mM CaCl2, 0.1 mM NaN3) and was placed into a Spectrosil quartz fluorometer cuvette. MMP at a concentration of 0.1 ~,M was mixed with varying amounts of chelating peptide having SEA ID No. 4 or 6 and incubated at 25 °C for 10 minutes to effect binding. The protein mixture was added to the collagen substrate and mixed.quickly. Fluorescence emission intensity at 520 nm was measured as a function of time (excitation wavelength 495 nm) in a Shimadzu RF5301 fluorometer. The fluorescein release assay was used to determine the inhibitory constant (K;) of the chelating peptide inhibitor ([I]) according to Segel (1993) via the use of Dixon plots (1/v vs. [I]), such that:
slope = Km / (V",~ Ki [S]) (1) where Km is the Michaelis constant, V",~ is the reaction maximum velocity, and [S] is the substrate concentration.
The second assay utilized the technique of fluorescence resonance energy transfer (FRET). The substrate peptide (Calbiochem.
#444221 ) comprised seven amino acids, coupled to a carboxyl terminal dinitrophenyl acceptor, and an amino terminal 2-aminobenzo-anthraniloyl (Abz) moiety donor. Cleavage of this substrate by MMP-9 results in the liberation of a fluorescent product (365 nm excitation, 450 nm emission). Peptide at a concentration of 5 ~,M was added to reaction buffer (50 mM Tris-HCl (pIi 7.6), 150 mM NaCI, 5 mM CaCl2, 0.1 mM
NaN3) and placed into a black 96-well microtiter plate well that had been previously blocked with 1% BSA. MMP at a concentration of 0.1 ~.M
was mixed with varying amounts of chelating peptide (0, 0.01, 0.02, 0.04, and 0.1 ~.M) and incubated at 25 °C for 10 minutes to effect binding. The protein mixture was added to the peptide substrate and mixed quickly. Fluorescence intensity as a function of time was measured with a Dynex MFX fluorescence microtiter plate reader.
Fluorescence intensity was related back to moles of peptide cleaved by producing a standard curve with an Abz containing non-FRET peptide.
Inhibitory constants were derived from the curves and are listed below in Table 2.
Table 2. Inhibitor Constants Peptide . Sequence Chelator K;(wM) ChePep-1 CSAVPVH (SEQ ID No. PSDE 98 4) ChePep-2 DSAVPVH (SEQ ID No. IDA 67 5) ChePep-3 IYTACMSAV (SEQ ID No. PSDE 350 6) ChePep-4 IYTACMSAV (SEQ ID No. IDA 163 6) ChePep-5 VHTHLCD (SEQ TD No. AFTA 221 7) ChePep-6 CTCVP (SEQ ID No. 8) AFTA 125 Example 5. Surface Plasmon Resonance The BiaCore-X surface plasmon resonance (SPR) device was utilized to measure the interaction between the chelating peptide (CP) and MMP-9. For these experiments a carboxymethyl dextran sensor chip (BiaCore, AB; CM-5, Lofas et al., 1993) was activated with 50 mM N-hydroxysuccinimide, 0.2 M N-ethyl-N'-(dimethylaminopropyl)-carbodiimide at a flow rate of 10 ~,L per minute for ten minutes. MMP-9 at a concentration of 75 ng1 ~,L was coupled to the activated surface at a flow rate of 10 ~,L per minute for ten minutes.
The final surface was inactivated by flowing 1 M ethanolamine-HCl at a rate of 10 ~,L per minute for five minutes over the sensor surface. CP
was flowed over the sensor surface at a rate of 20 ~,L per minute, and at concentrations of 10, 25, and 50 nM. Binding isotherms were evaluated by simultaneously fitting the forward (lca) and reverse (l~) rate constants to the following formula:
d[CP~MMP-9] /dt = (ka [CP] [MMP-9]) - (kd [CP~MMP-9]) (2) (Karlsson and Falt, 1997) where [CP], [MMP-9], and [CP~MMP-9] are the concentrations of free chelating peptide, free MMP-9, and the complex respectively. The equilibrium affinity constant (KA) is defined as:
KA=ka/kd (3) Equation 3 is expressed in terms of the SPR signal (Mortonet al., 1995) as:
dR/dt = kaCR,l;~ - (kaC + kd)R (4) where R is the SPR signal (in response units, RU) at time t, R",~is the maximum MMP-9 binding capacity in RU, and C is the chelating peptide concentration. Kinetic analysis (O' Shannessy et al., 1993) was performed using Origin from Microcal, Inc.
Example 6. Viability Assays The relative toxicity of the chelating and substrate peptides was assayed using the skin model Epiderm that is commercially available from MatTek Corp. The individual skin sample containers were preincubated in culture medium at 37 °C under 5% C02 for two hours prior to the addition of the peptide constructs. The sample containers were transferred to 6 well plates that contained fresh media.
All peptides were dissolved in PBS at a final concentration of 10 mM, and 100 ~.L of each peptide solution was pipetted onto the surface of the Epiderm sample container. Incubation was continued for 12 hours at 37 °C under 5% C02. After the incubation period, the sample containers were washed three times with PBS and the sample containers were transferred to a 24 well plate that contained 300~,L of MTT assay media per well (MTT concentration was 1 mglmL). The colorimetric~ assay was allowed to develop for three hours (incubation at 37°C under 5%
CO~). Sample containers were then transferred to a 24 well culture plate that contained 2 mL of isopropanol per well. Extraction of the colored precipitate occurred over a period of four hours at room temperature.
Absorbance readings were taken at 570 nm and 650 nm for each sample.
The percent viability of each sample relative to a PBS control was calculated as:
100 X (OD570Sam -- OI]65psam ~ OI] con - OD con ) ( 570 GSO ~ ( ) Routinely, each peptide sample was assayed in duplicate or triplicate.
Example 7.
A skin equivalent toxicity model (Epiderm) was employed to measure the overall cellular viability in the presence of the six peptide constructs. A single dose of 10 mM peptide (in PBS) was applied to the Epiderm samples for a period of 12 hours. The resulting viability is plotted in Figure 7. A PBS control is set to a value of ,100 percent viability. The surfactant Triton X-100 served as a negative control, that is the application of a 1 % triton solution should result in over 90% cell death. As can be seen in Figure 7, all six peptides exhibit about 94.2 +/-3.8 percent. Qf the three zinc chelators, AFTA seems to be slightly more toxic (90.5 % viability) than IDA (94.8 % viability) or PSDE (96.5 viability), although the viability differences are not significant.
<110> Quirk, Stephen Tyrrell, David <120> Design and Use of Advanced Zinc Chelating Peptides to Regulate Matrix Metalloproteinases <130> 44039-227522 11301-0200 <140> US 09/753,139 <141> 2000-12-29 <160> 10 <170> PatentIn version 3.0 <210> 1 <211> 7 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <220>
<221> VARIANT
<222> (2)..(2) <223> X = Ser or Thr <220>
<221> VARIANT
<222> (4)..(4) <223> X = Ser, Ala or Val <400> 1 Cys Xaa Cys Xaa Pro His Pro <210> 2 <21l> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <220>
<221> VARIANT
<222> (1)..(l) <223> X = Ile or Val <220>
<221> VARIANT
<222> (2)..(2) <223> X = Glu, Gln or Arg <220>
<221> VARIANT
<222> (3)..(3) <223> X = Phe or Tyr <220>
<221> VARIANT
<222> (4)..(4) <223> X = Ile or Val <220>
<221> VARIANT
<222> (5)..(5) <223> X = Tyr or His <220>
<221> VARIANT
<222> (7)..(7) <223> X = Ala, Pro or Glu <220>
<221> VARIANT
<222> (8)..(8) <223> X = Pro, Phe or Ala <220>
<221> VARIANT
<222> (9)..(9) <223> X = Ser, Asp or Met <220>
<221> VARIANT
<222> (10)..(10) <223> X = Ala or Ser <220>
<221> VARIANT
<222> (11)..(11) <223> X = Val or Leu <220>
<221> VARIANT
<222> (12)..(12) <223> X = Cys or Gly <400> 2 Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Xaa Xaa Xaa Xaa <210> 3 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Oligonucleotide <220>
<221> VARIANT
<222> (1)..(1) <223> X = Met, Val or Leu <220>
<221> VARIANT
<222> (2) .. (2) <223> X = His, Phe or Tyr <220>
<221> VARIANT
<222> (3)..(3) <223> X = Ile or Thr <220>
<221> VARIANT
<222> (4)..(4) <223> X = Thr, His or Gly <220>
<221> VARIANT
<222> (5)..(5) <223> X = Leu or Thr <220>
<221> VARIANT
<222> (7)..(7) <223> X = Asp, Asn or Ser <220>
<221> VARIANT
<222> (8)..(8) <223> X = Phe or Tyr <220>
<221> VARIANT
<222> (9)..(9) <223> X = Ile or Val <400> 3 Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa <210> 4 <211> 7 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Oligonucleotide <400> 4 Cys Ser Ala Val Pro Val His <210> 5 <211> 7 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <400> 5 Asp Ser Ala Val Pro Val His <210> 6 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <400> 6 Ile Tyr Thr Ala Cys Met Ser Ala Val <210> 7 <211> 7 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <400> 7 Val His Thr His Leu Cys Asp <210> 8 <211> 5 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <400> 8 Cys Thr Cys Val Pro <210> 9 <211> 4 <212> PRT
have been utilized, resulting in complete MMP inhibition. However, shutting off all MMP activity is actually deleterious to the healing process, as some MMP activity is required for tissue remodelling. For example, potent inhibition aimed at binding the zinc (II) site is toxic to humans because it shuts off bind to all zinc-containing enzymes. It is therefore necessary to have regulation be selective.
Thus, there is a need in the art for improved regulation of MMPs to promote healing of chronic and acute wounds.
There is also a need in the art for an inhibitor having relatively good affinity, which is selective.
Furthermore, there is a need in the art for MMP inhibitors that are not toxic to the individual to whom they are adminisered.
SUMMARY OF THE INVENTION
Using a novel approach to wound site proteinase management, the present invention, in one aspect, provides a new class of MMP regulators. These regulators comprise a zinc chelator covalently attached to a peptide that corresponds to a region of a TIMP
protein that directly interacts with an MMP molecule in the vicinity of the catalytic zinc molecule to bind wound site proteinases. The binding specificity of the peptide will bring the zinc chelator into molecular proximity of the MMP bound zinc in such a way as to allow ligation. In addition to this affinity, the exact sequence of the peptide will allow targeting of specific MMPs. This chemistry regulates the level of MMP
activity to a point that promotes healing. This provides a MMP regulator which can, with high affinity, selectively regulate MMP activity unlike known MMP regulators.
In another aspect, the present invention provides a method for making the new class of MMP regulators. The method comprises binding a zinc chelator to synthetic peptides. The peptide sequences chosen were the part of the TIMP that made the closest approach to the MMP n the vicinity of the catalytic zinc. The sequence is a common structural feature of the binding interface.
In yet another aspect, the present invention provides methods of treating chronic and/or acute skin wounds and other diseases in which MMPs play a role. These methods are advantageous over conventional methods in that they provide both improved selectivity and improved affinity. Additionally, the methods of the present invention provide selective binding to MMPs without causing potential harm to the individual being treated. This is accomplished through the use of novel MMP regulators including a zinc chelator attached to a TIMP derived peptide. These compositions are particularly effective at bind MMP
without compromising other zinc-dependent biochemical activities.
Finally, by applying these novel MMP regulators to an area to be treated, the present invention provides a method of controlling diseases cause by uncontrolled MMP activity without the use of toxic inhibitors.
Therefore, it is an object of the invention to provide new MMP regulators.
It is another object of the invention to provide MMP
regulators that comprises a zinc chelator and synthetic peptides containing novel amino acid sequences that bind to the TIMP binding region of the MMP.
It is yet another object of the invention to provide novel synthetic peptides for use in the production of the MMP regulators of the invention.
It is a further object of the present invention to provide a novel zinc chelator for use in the production of the MMP regulators of the invention.
It is an obj ect of the invention to provide synthetic peptides having SEQ ID Nos. 1, 2, and 3.
It is another object of the present invention to provide MMP
regulators comprising peptides having SEQ ID Nos. 1, 2, or 3 and a zinc chelator.
It is yet another object of the invention to provide methods for treating chronic and acute wounds.
It is a further object of the present invention to provide methods for treating angiogenic-associated diseases.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates a time course reaction of MMP-9 hydrolysis of fluoresceinated collagen in the presence of increasing amounts of the zinc chelating peptide. The curves (from top to bottom) represent MMP-9:ChePep-1 molar stoichiometries of 1:0, 1:0.25, 1:0.5, and 1:1. ChePep-1 is composed of PSDE coupled with the peptide having SEQ ID No. 4. The graph shows fluorescence as a function of time in the continuous assay.
Figure 2 depicts ChePep-2 regulation of MMP-9 via FRET
assay. ChePep-2 is composed of IDA coupled with a peptide having Seq ID No. 5. This mixture was added to the FRET substrate peptide in reaction buffer. Fluorescence measurements were made at the indicated times. The curves represent ChePep-2: MMP-9 molar stoichiometries of 0:1 (closed circles), 0.1:1 (open circles), 0.2:1 (closed squares), 0.3;1 (open squares).
Figure 3 represents ChePep-3 (closed squares) and ChePep-4 (open circles) regulation of MMP-9 via FRET assay. ChePep-3 is made by combining PSDE with a peptide having SEQ ID No. 6 and ChePep-4 is made by combining IDA with a peptide having SEQ ID No.
6. ChePeps were incubated with MMP-9 for 10 minutes to effect binding. This mixture was added to the FRET substrate peptide in reaction buffer. Fluorescence measurements were made at the indicated times. MMP-9 only control is shown for reference (closed circles).
ChePep:MMP-9 molar stoichiometry is 0.25:1.
Figure 4 illustrates ChePep-5 regulation of MMP-9 via FRET assay. ChePep-5 is composed of a AFTA combined with a peptide having SEQ ID No. 7. ChePep-5 was incubated with MMP-9 for 10 minutes to effect binding. This mixture was added to the FRET
substrate peptide in reaction buffer. Fluorescence measurements were made at the indicated times. The curves represent ChepPep-5: MMP-9 molar stoichiometries of 0:1 (closed circles), 0.1:1 (open circles), 0.2:1 (closed squares), 0.3:1 (open squares). Excitation was at 365 nm, and the emission was fixed at 450 nm.
Figure 5 shows ChePep-6 regulation of MMP-9 via the FRET assay. ChePep-6 is made by combining AFTA with a peptide having SEQ ID No. ~. ChePep-6 was incubated with MMP-9 for 10 minutes to effect binding. This mixture was added to the FRET
substrate peptide in reaction buffer. Fluorescence measurements (Excitation 365 nm, Emission450.nm) were made at the indicated times.
The curves represent ChepPep-6: MMP-9 molar stoichiometries of 0:1 (closed circles), 0.1:1 (open circles).
Figure 6 depicts SPR analysis of ChePep-6 binding to immobilized MMP-9 that is on the surface of a BiaCore CM-5 chip. The sensogram shows the relative SPR signal as a function of time for a 400 second association phase and an 800 second dissociation phase. Flow rate was maintained at a rate of 20 ~.L per minute.
Figure 7 represents compound viability assays. The graph plots the percent viability of the peptides utilized in this study relative to a PBS control. Error bars are +/-SD. Samples (left to right) are as follows: PBS positive control, 1%Triton X-100 negative control, ChePep-1, ChePep-2, ChePep-3, ChePep-4, ChePep-5, and ChePep-6.
Figure 8 is a reaction scheme for modification of EDTA to PSDE to allow coupling of the EDTA chelator to the peptides of the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
MMPs contain a zinc molecule located in the active site.
This zinc molecule intimately participates in the chemistry of degrading collagen. As a result, if the zinc is blocked or removed, enzymatic activity of the MMP can be inhibited. The present invention provides compositions (referred to herein as ChePeps) for the regulation of MMP
activity. These compositions comprise a zinc chelator that is covalently attached to a TIMP-derived peptide. The zinc chelator is any compound that binds zinc, whether or not the molecule is a true chelator. The TIMP-derived peptide corresponds to a region of the TIMP protein that directly interacts with the MMP molecule in the vicinity of the catalytic zinc molecule. The binding specificity of this peptide assists in bringing the zinc chelator into molecular proximity with the MMP bound zinc in such a way as to allow ligation of the zinc from the MMP. In addition to this affinity, the exact sequence of the peptide will allow targeting of specific MMPs. This chemistry regulates the level of MMP activity to a point that promotes healing.
Preferably, modern molecular modeling methodologies are employed to design the novel peptides of the present invention that can bind to the zinc (II) site of MMPs and, therefore, regulate a broad range of MMPs. Analysis of the three-dimensional structure of the various MMPs and TIMPs, and . the chemical nature and identification of conserved and variant amino acids in the MMP-TIMP contact interface, is preferably accomplished through molecular modeling utilizing two visualization programs, Swiss PDB Viewer (Guex and Peitsch, 1997) and Rasmol (Sayle and Milner-White, 1995). The present inventors.
have found through visualization of TIMP~MMP complexes that the TIMP molecules make significant contact with the area surrounding the MMP active site.
Other investigators have explored the interaction between MMPs and TIMPs. (Butler et al. (1999) J. Biol. Chem. 274, 20391-96;
Overall et al. (1999) J. Biol. Chem. 274, 4421-29; Menget al. (1999) J.
Biol. Chem. 274, 10184-89). In one embodiment, the present invention comprises derivation of peptides from TIMP proteins that comprise structures in accordance with the three regions of the TIMP proteins that are in close proximity to the MMP catalytic zinc.
In another embodiment, the novel synthetic peptides of the present invention comprise relatively short stretches of amino acids that correspond to the TIMP/MMP binding domain. These peptides can be coupled to a zinc chelator and are capable of binding many MMP
enzymes in the region of the catalytic zinc.
In a preferred embodiment, the present invention comprises thr ee peptides derived from TIMP regions that have a large number of specific side chain interactions with MMPs. The exact sequence of the peptide employed allows targeting of specific MMPs. These sequences are derived from three separate regions of TIMPs I-IV that contact MMPs.
These preferred peptides comprise the amino acid sequences designated as SEQ ID Nos. 1-3. These sequences are shown in Table 1 below. The peptide having SEQ ID No. 1 spans MMP amino' acids 2-9. These peptides are seven amino acids in length. The peptide having SEQ ID No. 2 spans MMP amino acids 62-73 and is 12 amino acids in length. The peptide having SEQ ID No. 3 is 9 amino acids in length encompasses MMP residues 97-105.
Within these preferred peptides, there is a large degree of sequence variation, as denoted by positions in parentheses. This variability can be used as a tool to modulate binding affinity and specificity of TIMP binding interactions. The exact sequence of the:
peptide can be altered to modulate binding affinity and/or specificity, so long as there is a single cysteine residue in the peptide. These three preferred peptides can be further modified by C-ter amidation and N-ter acetylation. This charge neutralization is often found to increase binding affinity as it mimics the peptide being in the context of a whole protein.
In sum, these specific peptides allow for altering the level of specific MMPs in a coordinated manner.
Table 1. Peptide Family Sequences SEQ ID No. C-(S/T)-C-(S/A/V)-P-H-P
SEQ ID No. (I/V)-(E/Q/R)-(F/Y)-(I/V)-(Y/H)-T-(A/P/E)-(P/F/A)-(S/D/M)-(A/S)-(V/L)-(C/G) SEQ ID No. (M/V/L)-(H/F/Y)-(I/T)-(T/H/G)-(L/T)-C-(D/N/S)-(F/Y)-(I/V) While not wishing to be bound by the following theory, it appears that the preferred ChePep complexes block the imino carboxylate groups via zinc chelation prior to activating the remaining carboxyl group for coupling to the peptides. Once liganded to the zinc ion, these carboxyl groups are not able to participate in the activation reaction. The zinc binding affinity is high enough to ensure a slow off rate, so that the liganding carboxyls are bound to the zinc throughout the NHS/EDC reaction. (See examples) The zinc ion is then removed by extensive dialysis. For example, the material can be dialyzed through a 500 MWCO cellulose acetate dialysis tube against 50% phosphate buffered saline (PBS)/water, preferably at room temperature for 48 hours.
In a preferred embodiment, the zinc chelator is a molecule that contains a diacetic acid moiety and ,thus, a good chelator of certain divalent cations, including zinc. Although these compounds are preferred, any small organic molecule that has the ability to ligand or, chelate a zinc molecule can sterically access the MMP active site (without making any deleterious electrostatic interactions) is capable of incorporation into a chelating peptide (ChePep). The chelation process itself is not specific, in that any zinc is potentially a chelation target.
Possible chelators include, but are not limited to, EDTA, EGTA, DTPA, CDTA, HEDTA, NTA, citric acid, salicylic acid, and malic acid. Other chelators include peptides that can bind zinc. For example, peptides SEQ ID No. 9 (CDIC) or SEQ ID No. 10 (HTITH) chelate the zinc moiety through interactions with the two cysteines (SEQ ID No. 9) or the two histidines (SEQ ID No. 10). These sequences are derived from the consensus structure of the zinc finger motif described by Berg (Berg et al., Ann Rev Biophys Biomol Struct, 1997, 26: 357-71. These peptides can be coupled to the targeting peptide via standard peptide synthesis.
In a preferred embodiment, one of three zinc chelating molecules is covalently attached to one of the several TIMP derived peptides that comprise the present invention. The chemical structures of.
these three zinc chelating molecules: pyridine disulfide ethylenediaminetetraacetic acid (PSDE), amino-iminodiacetic acid (IDA), and 2-amino-4-fluorophenol N,N, O triacetic acid (AFTA), are depicted below in Structure 1.
Structure 1 ooc~rr ~N ~~N
H
ooC~N
PSDE
oOC
ooc~N ooc' AFTA
Pyridine disulfide ethylenediaminetetraacetic acid (PSDE) of the present invention is produced in a literature synthesis. (Hayward et al (1995), J. Org. Chem. 60, 3924-27) Covalent coupling of PDSE to the peptide is carried out by a simple stoichiometric disulfide exchange with a cysteine at the amino terminus. Typically the process results in a.
substantially pure product with an overall yield of about 10-25 percent.
The peptide sequence shown in Structure 2 below is a modification of SEQ ID No. 1 wherein the cysteine in position 3 is replaced with an alanine. This molecule can be directly coupled to any free thiol via a simple disulfide exchange reaction.
Structure 2 ooc s~
o s I
ooC~N ~ H~
~N
OOC~ N I I
OOC
Peptide sequences: C
C(T/S)X(S/V/A)P(P/V/S/A)H
In another embodiment, the present invention provides PSDE be coupled to SEQ ID No. 4 (CSAVPVH) with an overall yield of 80 percent. The reaction product is then purified via RP-HPLC as described in the Example. Introduction of this molecule, ChePep-l, to MMP-9 prevents the enzyme from degrading fluoresceinated collagen in a dose dependent manner as is shown in Figure 1.
In yet another embodiment, the present invention provides creation of a combined regulator (binding specificity via the peptide and zinc chelation via the small molecule) by covalently joining EDTA or IDA to a TIMP derived peptide sequence. Ethylenediaminetetraacetic acid (EDTA) and iminodiacetic acid (IDA) are potent chelators of zinc.
However, an EDTA chelator needs some prior literature synthesis in order to perform a coupling reaction preferred by the present invention.
This synthesis is described by Hayward et al. (J. Org. Chem., Vol 60(12), 1995, 3924-3927) and is presented in Figure 8. Such synthesis is not required for IDA because it is relatively easy to couple IDA to the carboxylate group of an aspartate that has been converted into a~
succinimide ester upon reaction with N-hydroxysuccinimide (NHS)/ N-ethyl-N'-(dimethylaminopropyl)carbo-diimide (EDC) (EDC/NHS).
By coupling IDA to a similar peptide, SEQ ID No. 5 (DSAVPVH), the effect of the size of the EDTA moiety on ChePep-1 (PSDE and SEQ ID No.4) can be determined. In this instance, the carboxylate group of the N-ter peptide aspartic acid is activated to a succinimide ester via incubation with EDC/NHS. This straightforward reaction is commonly used to link free amino groups with activated carboxylates. The general structure of a peptide that is covalently coupled to IDA through an activated aspartic acid carboxylate is shown below in Structure 3.
Structure 3 0OC\
00c~rI1 Peptide Sequences:
D (T/S) X (S/V/A) P (P/V/S/A) H
HN O
O=C
CHZ
H2N- ~ H-C-~- U U
Preferably, the entire synthetic scheme that couples IDA to the peptide and purifies the final product proceeds with an overall 49, percent yield. To avoid possible contaminants in the reaction, use a peptide with a C-ter amide group. Hence the only free carboxyl group in the peptide should be the aspartic acid sidechain.
The molecule ChePep-2 (IDA and SEA ID No. 5) regulates.
MMP-9 in the fluorescence resonance energy transfer (FRET) assay in a dose dependent manner. The construct is significantly more effective in regulating MMP-9 than was ChepPep-1, as demonstrated in Figure 2.
This may be due to the ability of an IDA moiety to more effectively ligate the active site zinc than PSDE because of stearic considerations as well as the need to satisfy charge interactions with the second chelating group on PSDE. In addition, the neutralization of the C-ter negative charge on the peptide via the amidation may also alter binding affinity.
In another embodiment, PSDE is coupled to a peptide of SEQ ID No. 2. Specifically, PSDE is coupled to a peptide having SEQ
ID No. 10 that is aminated at the amino terminus (IYTACMSAV-NH2) via the same disulfide exchange reaction previously discussed. The yield for the final product was 37%. The generalized structure of a chelating peptide (ChePep) composed of PSDE and SEQ ID No. 2 is shown below.
Structure 4 ooc ooC~N ~ HZ
N
a oOC~N O 6 00cJ
Peptide Sequences:
(I/V) (Y/I~ T (P/A/E) C (S/M/D) (E/S) (S/A) (V/L) If the cysteine residue in the fifth position of the above molecule is altered to aspartic acid, then IDA can be incorporated into the structure at the same position. In a preferred embodiment, IDA is coupled to SEQ ID No. 2, specifically, the peptide of SEQ ID No. 11 via the EDC/NHS reaction described in the Examples section. The final product yield was 75 percent. RP-HPLC chromatograms of both ChePep molecules revealed a single 214 nm absorbing peak.
Both ChePep-3 (PSDE and SEQ ID No. 6) and ChePep-4 (IDA and SEQ ID No. 6) show nearly identical ability to regulate MMP=
9 in the standard FRET assay. The time dependent regulation course is displayed in Figure 3. Despite the fact that there are differences between IDA and PSDE, molecular modeling indicates that the chelating groups of both ChePep constructs have similar accessibility to the MMP active, site zinc. In fact, the second chelating group of PSDE does not make any energetically unfavorable interactions that would lower binding affinity. It is believed that ChePep-3 may gain some binding energy by the interaction of the carboxylate oxygen on the free liganding moiety with a MMP-9 backbone amide.
Molecules like 2-amino-4-fluorophenolN,N, 0 triacetic acid (AFTA) are not, according to scientific literature, generally known or used as metal chelators, but can in fact readily chelate zinc in this application. AFTA is found to bind well into the active site of MMP-like enzymes. The diacetate group off the 2 ring position chelates the Z111C. The third acetate group can be used to couple a peptide to the molecule. The electronegative fluorine may also contribute to MMP
regulation by making specific interactions in the enzyme active site. The general structure of SEQ ID No. 3 covalently linked to AFTA is depicted below.
Structure 5 F
O
O~HN 2 3 N
COO COO
Peptide sequences:
C(T/S)x(S/V/A)P(P/V/S/A)H C . ~~ I-The above structure is created by coupling a peptide having SEQ ID No. 7 (VHTHLCD) to an AFTA zinc chelator using the same EDCMS chemistry previously described, except that the activated carboxyl group was donated by the AFTA moiety. Since there are three free carboxyl groups found on AFTA, only two of which can participate in zinc ligation (see Structure 1 ), it is necessary to make those chelating groups unreactive to EDC/NHS treatment. This can be accomplished by mixing AFTA with zinc sulfate prior to EDC/NHS activation. The zinc ion is chelated by the iminodiacetic acid moiety, leaving a single free carboxylate. The succinimide ester is then formed on this group as described in the Examples section. The activated AFTA-zinc complex is coupled to the N-ter amino group of the peptide, and the resulting molecule (ChePep-5) is purified to homogeneity by RP-Phase HPLC., Preferably, the total recovery yield was 61 % and the final material is judged to be 97% pure. The generalized structure of this type of regulator, shown in Structure 5, is capable of preventing the hydrolysis of the FRET peptide in a dose dependent manner.
In fact, according to the molar stoichiometries test depicted in Figure 4, ChePep-5 proves to be a better regulator than the TDA or the PSDE based chelating peptides. Its success can be attributed to, but not limited to, four factors: the fluorine group which, because of its electron negativity, tenaciously binds to proteins; the ring itself, being hydrophobic, binds well to the hydrophobic active site of the MMP; the presence of three carboxyl groups to bind to allow for zinc chelation;
and the amino groups to create specificity.
In another embodiment of this invention, a second AFTA
peptide construct is synthesized. This peptide (ChePep-6) comprises SEQ ID No. ~ (CTCVP) and an AFTA, with the AFTA molecule coupled to the peptide amino terminus. Coupling is preferably performed by first mixing an equal amount of zinc sulfate and AFTA.
The resulting complex is then activated with NHS/EDC. An amide coupling is then performed using the N-ter region of the peptide.
Alternatively, AFTA can be linked to the cysteine thiol via a disulfide exchange reaction. The structure of the preferred chelating peptide is shown in Structure 6 below.
Structure 6 This chelating peptide possesses the ability to prevent the hydrolysis of the FRET substrate peptide in the standard assay. As seen in Figure 5, ChePep-6 is an effective MMP-9 regulator at low molar stoichiometries.
In addition, ChePep-6 binds quickly and with high affinity; and once bound, ChePep-6 does not dissociate as seen in Figure 6. In fact, the combination of a group I peptide and an AFTA moiety resulted in the most potent regulator of all the ChePeps.
In another aspect, the present invention comprises the treatment of chronic and acute wounds. By applying the composition to the chronic wound, MMP activity can be regulated. Specifically, the composition comprises a peptide with binding specificity to bring the zinc chelator into molecular proximity of the MMP bound zinc in such a way as to allow ligation. In addition to this affinity, the exact sequence of the peptide will allow targeting of specific MMPs. This chemistry regulates the level of MMP activity to a point that promotes healing.
A highlight of this peptide based therapy is the plasticity in which this material can be applied to a chronic wound. Where the infection is localized to the skin, a preferred formulation is an ointment, lotion or other topical formulation. The composition for topical application useful in the present invention can be made into a variety of product types. These include, but are not limited to, creams, gels, sticks,.
sprays, pastes, mousses, or any aqueous medium. These product types can comprise several types of carrier systems including, but not limited to, solutions, dispersions, emulsions, gels, solids, and liposomes.
Additionally, the peptides can be introduced into the wound bed in a continuous manner via delivery by the wound bandage material itself.
Preferred dose ranges for treatment of chronic wounds are between approximately 0.01 and 1.0 mg/mL
Finally, another embodiment of the present invention is to~
control specific MMP activity. Certain diseases are caused by uncontrollable MMP activity. In fact, some diseases are caused by only a certain of the nine MMP molecules. By designing peptides that correspond with a specific MMP's active site, and then combining a zinc chelator to the peptide, only targeted MMP activity is regulated with a high degree of affinity and specificity.
The present invention is non-toxic in a skin equivalent model. The generally toxic effects of a non-specific zinc chelator are.
mitigated by the fact that the peptide portion of the ChePep construct directly targets the construct to the MMP active site in such a way as to minimize chelation at secondary (non MMP) targets.
The present invention is further illustrated and supported by the following examples. However, these examples should in no way be considered to further limit the scope of the invention. To the contrary, one having ordinary skill in the art would readily understand that there are other embodiments, modifications, and equivalents of the present invention without departing from the spirit of the present invention and/or the scope of the appended claims.
BASIC PROCEDURES
All peptides were synthesized by Sigma-Genosys, Inc.
using conventional techniques. The released peptides were purified to >95% homogeneity via RP-HPLC by the company. The pooled eluted peak material was desalted and lyophilized. Mass Spec analysis confirmed the peptide molecular weight and purity. Unless otherwise noted, all chemicals were purchased from Sigma Chemical Corp. or from Fluka Chemical Co. Active MMP-9 enzyme Was 'purchased from Calbiochem.
Molecular modeling utilized two visualization programs, Swiss PDB Viewer (Guex and Peitsch, 1997) and Rasmol (Sayle and Milner-White, 1995). Model work was performed on a Compaq PC
running Windows 95, as well as a Silicon Graphics, Inc. Octane UNIX
workstation. Additionally, the Cerius2 molecular package from Molecular Simulations, Inc. was utilized on the Octane. Three dimensional structure files were downloaded from the Protein Databank as follows (filename, reference): MMP-1 (1FBL, Li et al., 1995), MMP-2 (1GEN, Libson et al., 1995), MMP-8 (1JA0, 1JAN, Grams, et al., 1995; Reinemer et al., 1994), MMP-9 (1MM~, Browner et al., 1995), TIMP-2/MT-1 MMP complex (1BUV, Fernandez-Catalan et al., 1998), TIMP-2 ( 1 BR9, Tuuttila et al., 1998), and TIMP-1 /MMP complex (lUEA, Gomis-Ruth et al., 1997; Huang et al., 1996; Becker et al., 1995). These files were used to analyze the three-dimensional structure 2~
of the proteins, and the chemical nature and identification of conserved and variant amino acids in the MMP-TIMP contact interface. This information was utilized to design a minimalist peptide that could be coupled to a zinc chelator that would bind many MMP enzymes in the region of the catalytic zinc.
EXAMPLE 1. IDA Chelatin~ Peptides Peptide was resuspended in water to a final concentration of 100 mM. The amino form of IDA was dissolved in a small amount of DMSO followed by the slow addition of water until the compound was at a concentration of 150 mM. To the IDA solution was added N-.
hydroxysuccinimide (NHS), to a final concentration of 175 mM and N-ethyl-N'-(dimethylaminopropyl)-carbodiimide (EDC) to a final concentration of 400 mM. The solution was incubated at 37 °C with gentle stirring for 30 minutes. The previously prepared peptide solution was added to this reaction slowly over a period of 5 minutes. Stirring continued for an additional 30 minutes. The reaction was quenched by the addition of ethanolamine-HCl to a final concentration of 1.0 M. The final mixture was taken to dryness in a rotovac over a period of 10 hours.
The solid material was then resuspended in 500 p,L of water and the chelating peptide was purified away from unreacted species via RP-HPLC. A 250 mm x 100 mm, 5 ml Hypersil ODS-2 RP column was chromatographed with a mobile phase of A: 0.1 % TFA/water, B: 0.1 TFA/acetronitrile. After sample injection, a gradient of 100%A (0 to 2 min) and 0-60% B (2 to 25 min) was applied. The chelating peptide was detected at 214 nm and was 96% pure by peak integration. The eluting peaks were pooled, mixed with 3 volumes of water, and lyophilized.
The resulting powder was resuspended in water and dialyzed through a 500 MWCO cellulose acetate dialysis tube versus 50% phosphate buffered saline (PBS)/water. Chelating peptide was aliquoted and stored frozen at -20 °C.
Example 2. AFTA Chelating Peptides AFTA (50 mg) was dissolved in a small amount of DMSO
followed by the slow addition of water until the compound was at a concentration of 200 mM. To this solution was added zinc sulfate to a final concentration of 300 mM. This solution was stirred slowly at room temperature for 1 S minutes. The sample was then treated with EDC/NHS as described in Example 1. The resulting AFTA-succinamide ester was coupled with a peptide having SEQ ID No. 7 or 8, and the resulting peptide was purified as discussed in Example 1. After lyophilization, the AFTA-peptide was resuspended in water, and it was extensively dialyzed versus water in a 500 MWCO cellulose acetate dialysis tube. The absence of zinc ion was confirmed by atomic absorption spectroscopy.
Example 3. PSDE Chelating Peptides PSDE was prepared according to the method of Hayward et al (1995). This material was coupled directly to a stoichiometric amount of a cysteine containing peptide having SEQ ID No. 4 or 6 by the following disulfide exchange reaction. PSDE in an amount of 100 mM
in water and peptide in an amount of 100 mM in 25 mM Tris-HCl (pH' 7.2) were mixed and allowed to react for 45 minutes at 30 °C. The product was purified from the reactants by dialysis versus 10 mM Tris-HCl (pH 7.2) in a 500 MWCO cellulose acetate dialysis tube. The product was further purified by RP-HPLC as described in Example 1.
Example 4. Regulation of MMPs Two enzymatic assays were performed. The first assay measured the enzymatic hydrolysis of fluoresceinated collagen by MMP-9 as a function of time. Fluoresceinated collagen (Molecular Probes, Inc.), at a concentration of 5 ~.M was added to reaction buffer (50 mM Tris-HCl (pH 7.6), 150 mM NaCI, 5 mM CaCl2, 0.1 mM NaN3) and was placed into a Spectrosil quartz fluorometer cuvette. MMP at a concentration of 0.1 ~,M was mixed with varying amounts of chelating peptide having SEA ID No. 4 or 6 and incubated at 25 °C for 10 minutes to effect binding. The protein mixture was added to the collagen substrate and mixed.quickly. Fluorescence emission intensity at 520 nm was measured as a function of time (excitation wavelength 495 nm) in a Shimadzu RF5301 fluorometer. The fluorescein release assay was used to determine the inhibitory constant (K;) of the chelating peptide inhibitor ([I]) according to Segel (1993) via the use of Dixon plots (1/v vs. [I]), such that:
slope = Km / (V",~ Ki [S]) (1) where Km is the Michaelis constant, V",~ is the reaction maximum velocity, and [S] is the substrate concentration.
The second assay utilized the technique of fluorescence resonance energy transfer (FRET). The substrate peptide (Calbiochem.
#444221 ) comprised seven amino acids, coupled to a carboxyl terminal dinitrophenyl acceptor, and an amino terminal 2-aminobenzo-anthraniloyl (Abz) moiety donor. Cleavage of this substrate by MMP-9 results in the liberation of a fluorescent product (365 nm excitation, 450 nm emission). Peptide at a concentration of 5 ~,M was added to reaction buffer (50 mM Tris-HCl (pIi 7.6), 150 mM NaCI, 5 mM CaCl2, 0.1 mM
NaN3) and placed into a black 96-well microtiter plate well that had been previously blocked with 1% BSA. MMP at a concentration of 0.1 ~.M
was mixed with varying amounts of chelating peptide (0, 0.01, 0.02, 0.04, and 0.1 ~.M) and incubated at 25 °C for 10 minutes to effect binding. The protein mixture was added to the peptide substrate and mixed quickly. Fluorescence intensity as a function of time was measured with a Dynex MFX fluorescence microtiter plate reader.
Fluorescence intensity was related back to moles of peptide cleaved by producing a standard curve with an Abz containing non-FRET peptide.
Inhibitory constants were derived from the curves and are listed below in Table 2.
Table 2. Inhibitor Constants Peptide . Sequence Chelator K;(wM) ChePep-1 CSAVPVH (SEQ ID No. PSDE 98 4) ChePep-2 DSAVPVH (SEQ ID No. IDA 67 5) ChePep-3 IYTACMSAV (SEQ ID No. PSDE 350 6) ChePep-4 IYTACMSAV (SEQ ID No. IDA 163 6) ChePep-5 VHTHLCD (SEQ TD No. AFTA 221 7) ChePep-6 CTCVP (SEQ ID No. 8) AFTA 125 Example 5. Surface Plasmon Resonance The BiaCore-X surface plasmon resonance (SPR) device was utilized to measure the interaction between the chelating peptide (CP) and MMP-9. For these experiments a carboxymethyl dextran sensor chip (BiaCore, AB; CM-5, Lofas et al., 1993) was activated with 50 mM N-hydroxysuccinimide, 0.2 M N-ethyl-N'-(dimethylaminopropyl)-carbodiimide at a flow rate of 10 ~,L per minute for ten minutes. MMP-9 at a concentration of 75 ng1 ~,L was coupled to the activated surface at a flow rate of 10 ~,L per minute for ten minutes.
The final surface was inactivated by flowing 1 M ethanolamine-HCl at a rate of 10 ~,L per minute for five minutes over the sensor surface. CP
was flowed over the sensor surface at a rate of 20 ~,L per minute, and at concentrations of 10, 25, and 50 nM. Binding isotherms were evaluated by simultaneously fitting the forward (lca) and reverse (l~) rate constants to the following formula:
d[CP~MMP-9] /dt = (ka [CP] [MMP-9]) - (kd [CP~MMP-9]) (2) (Karlsson and Falt, 1997) where [CP], [MMP-9], and [CP~MMP-9] are the concentrations of free chelating peptide, free MMP-9, and the complex respectively. The equilibrium affinity constant (KA) is defined as:
KA=ka/kd (3) Equation 3 is expressed in terms of the SPR signal (Mortonet al., 1995) as:
dR/dt = kaCR,l;~ - (kaC + kd)R (4) where R is the SPR signal (in response units, RU) at time t, R",~is the maximum MMP-9 binding capacity in RU, and C is the chelating peptide concentration. Kinetic analysis (O' Shannessy et al., 1993) was performed using Origin from Microcal, Inc.
Example 6. Viability Assays The relative toxicity of the chelating and substrate peptides was assayed using the skin model Epiderm that is commercially available from MatTek Corp. The individual skin sample containers were preincubated in culture medium at 37 °C under 5% C02 for two hours prior to the addition of the peptide constructs. The sample containers were transferred to 6 well plates that contained fresh media.
All peptides were dissolved in PBS at a final concentration of 10 mM, and 100 ~.L of each peptide solution was pipetted onto the surface of the Epiderm sample container. Incubation was continued for 12 hours at 37 °C under 5% C02. After the incubation period, the sample containers were washed three times with PBS and the sample containers were transferred to a 24 well plate that contained 300~,L of MTT assay media per well (MTT concentration was 1 mglmL). The colorimetric~ assay was allowed to develop for three hours (incubation at 37°C under 5%
CO~). Sample containers were then transferred to a 24 well culture plate that contained 2 mL of isopropanol per well. Extraction of the colored precipitate occurred over a period of four hours at room temperature.
Absorbance readings were taken at 570 nm and 650 nm for each sample.
The percent viability of each sample relative to a PBS control was calculated as:
100 X (OD570Sam -- OI]65psam ~ OI] con - OD con ) ( 570 GSO ~ ( ) Routinely, each peptide sample was assayed in duplicate or triplicate.
Example 7.
A skin equivalent toxicity model (Epiderm) was employed to measure the overall cellular viability in the presence of the six peptide constructs. A single dose of 10 mM peptide (in PBS) was applied to the Epiderm samples for a period of 12 hours. The resulting viability is plotted in Figure 7. A PBS control is set to a value of ,100 percent viability. The surfactant Triton X-100 served as a negative control, that is the application of a 1 % triton solution should result in over 90% cell death. As can be seen in Figure 7, all six peptides exhibit about 94.2 +/-3.8 percent. Qf the three zinc chelators, AFTA seems to be slightly more toxic (90.5 % viability) than IDA (94.8 % viability) or PSDE (96.5 viability), although the viability differences are not significant.
<110> Quirk, Stephen Tyrrell, David <120> Design and Use of Advanced Zinc Chelating Peptides to Regulate Matrix Metalloproteinases <130> 44039-227522 11301-0200 <140> US 09/753,139 <141> 2000-12-29 <160> 10 <170> PatentIn version 3.0 <210> 1 <211> 7 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <220>
<221> VARIANT
<222> (2)..(2) <223> X = Ser or Thr <220>
<221> VARIANT
<222> (4)..(4) <223> X = Ser, Ala or Val <400> 1 Cys Xaa Cys Xaa Pro His Pro <210> 2 <21l> 12 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <220>
<221> VARIANT
<222> (1)..(l) <223> X = Ile or Val <220>
<221> VARIANT
<222> (2)..(2) <223> X = Glu, Gln or Arg <220>
<221> VARIANT
<222> (3)..(3) <223> X = Phe or Tyr <220>
<221> VARIANT
<222> (4)..(4) <223> X = Ile or Val <220>
<221> VARIANT
<222> (5)..(5) <223> X = Tyr or His <220>
<221> VARIANT
<222> (7)..(7) <223> X = Ala, Pro or Glu <220>
<221> VARIANT
<222> (8)..(8) <223> X = Pro, Phe or Ala <220>
<221> VARIANT
<222> (9)..(9) <223> X = Ser, Asp or Met <220>
<221> VARIANT
<222> (10)..(10) <223> X = Ala or Ser <220>
<221> VARIANT
<222> (11)..(11) <223> X = Val or Leu <220>
<221> VARIANT
<222> (12)..(12) <223> X = Cys or Gly <400> 2 Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Xaa Xaa Xaa Xaa <210> 3 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Oligonucleotide <220>
<221> VARIANT
<222> (1)..(1) <223> X = Met, Val or Leu <220>
<221> VARIANT
<222> (2) .. (2) <223> X = His, Phe or Tyr <220>
<221> VARIANT
<222> (3)..(3) <223> X = Ile or Thr <220>
<221> VARIANT
<222> (4)..(4) <223> X = Thr, His or Gly <220>
<221> VARIANT
<222> (5)..(5) <223> X = Leu or Thr <220>
<221> VARIANT
<222> (7)..(7) <223> X = Asp, Asn or Ser <220>
<221> VARIANT
<222> (8)..(8) <223> X = Phe or Tyr <220>
<221> VARIANT
<222> (9)..(9) <223> X = Ile or Val <400> 3 Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa <210> 4 <211> 7 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Oligonucleotide <400> 4 Cys Ser Ala Val Pro Val His <210> 5 <211> 7 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <400> 5 Asp Ser Ala Val Pro Val His <210> 6 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <400> 6 Ile Tyr Thr Ala Cys Met Ser Ala Val <210> 7 <211> 7 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <400> 7 Val His Thr His Leu Cys Asp <210> 8 <211> 5 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <400> 8 Cys Thr Cys Val Pro <210> 9 <211> 4 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <400> 9 Cys Asp Ile Cys <210> 10 <211> 5 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <400> 10 His Thr Ile Thr His
<223> Synthetic Peptide <400> 9 Cys Asp Ile Cys <210> 10 <211> 5 <212> PRT
<213> Artificial Sequence <220>
<223> Synthetic Peptide <400> 10 His Thr Ile Thr His
Claims (23)
1. An MMP regulator comprising a zinc chelator and a TIMP-derived peptide.
2. The regulator of Claim 1 wherein the zinc chelator is selected from the group consisting of EDTA, EGTA, DTPA, CDTA, HEDTA, NTA, IDA, PSDE, AFTA, citric acid, salicylic acid, and malic acid.
3. The regulator of Claim 2 wherein the zinc chelator is IDA, PSDE, or AFTA.
4. The regulator of Claim 1 wherein the zinc chelator is selected from the group consisting of SEQ ID Nos. 9 and 10.
5. The regulator of Claim 1 wherein the peptide comprises SEQ ID
No. 1-3.
No. 1-3.
6. The regulator of Claim 4 wherein the peptide is selected from the group consisting of SEQ ID Nos. 4, 5, 6, 7, 8 and 11.
7. The regulator of Claim 1 wherein the peptide contains at least one cysteine residue.
8. A method of treating chronic or acute wounds comprising administering an MMP regulator comprising a zinc chelator and a TIMP-derived peptide.
9. The method of Claim 8 wherein the zinc chelator is selected from the group consisting of EDTA, EGTA, DTPA, CDTA, HEDTA, NTA, IDA, PSDE, AFTA, citric acid, salicylic acid, and malic acid.
10. The method of Claim 9 wherein the zinc chelator is IDA, PSDE, or AFTA.
11. The method of Claim 8 wherein the zinc chelator is selected from the group consisting of SEQ ID Nos. 9 and 10.
12. The method of Claim 8 wherein the peptide comprises SEQ ID
No. 1-3.
No. 1-3.
13. The method of Claim 12 wherein the peptide is selected from the group consisting of SEQ ID Nos. 4, 5, 6, 7, 8 and 11.
14. The method of Claim 8 wherein the peptide contains at least one cysteine residue.
15. A composition comprising a pharmaceutically acceptable carrier and an MMP regulator, wherein the MMP regulator comprises a zinc chelator and a TIMP-derived peptide.
16. The composition of Claim 15, wherein the composition is in topical form.
17. The composition of Claim 15, wherein the composition is in the form of a lotion, ointment, cream, gel, stick, spray, paste, mousse, solution, dispersion, emulsion, solid, and liposome.
18. The regulator of Claim 15 wherein the zinc chelator is selected from the group consisting of EDTA, EGTA, DTPA, CDTA, HEDTA, NTA, IDA, PSDE, AFTA, citric acid, salicylic acid, and malic acid.
19. The regulator of Claim 18 wherein the zinc chelator is IDA, PSDE, or AFTA.
20. The regulator of Claim 15 wherein the zinc chelator is selected from the group consisting of SEQ ID Nos. 9 and 10.
21. The regulator of Claim 15 wherein the peptide comprises SEQ ID
No. 1-3.
No. 1-3.
22. The regulator of Claim 21 wherein the peptide is selected from the group consisting of SEQ ID Nos. ,4, 5, 6, 7, 8 and 11.
23. The regulator of Claim 15 wherein the peptide contains at least one cysteine residue.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/753,139 | 2000-12-29 | ||
| US09/753,139 US7041787B2 (en) | 2000-12-29 | 2000-12-29 | Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases |
| PCT/US2001/049276 WO2002053173A2 (en) | 2000-12-29 | 2001-12-21 | Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2431853A1 true CA2431853A1 (en) | 2002-07-11 |
Family
ID=25029322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002431853A Withdrawn CA2431853A1 (en) | 2000-12-29 | 2001-12-21 | Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7041787B2 (en) |
| EP (1) | EP1348024B1 (en) |
| KR (1) | KR100818874B1 (en) |
| AT (1) | ATE342352T1 (en) |
| AU (1) | AU2002231087A1 (en) |
| CA (1) | CA2431853A1 (en) |
| DE (1) | DE60123833T2 (en) |
| MX (1) | MXPA03005903A (en) |
| WO (1) | WO2002053173A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6989139B2 (en) * | 2000-02-15 | 2006-01-24 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| CA2492143A1 (en) * | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
| US20100131001A1 (en) * | 2008-11-24 | 2010-05-27 | Medtronic Vascular, Inc. | Targeted Drug Delivery for Aneurysm Treatment |
| US20100131051A1 (en) * | 2008-11-24 | 2010-05-27 | Medtronic Vascular, Inc. | Systems and Methods for Treatment of Aneurysms Using Zinc Chelator(s) |
| WO2010070076A1 (en) | 2008-12-19 | 2010-06-24 | Crystax Pharmaceuticals, S.L. | Alkanoic acid derivatives and their therapeutic use as hdac inhibitors |
| KR101363455B1 (en) * | 2011-09-09 | 2014-02-21 | (주)케어젠 | Peptides Inhibiting the Activity of Matrix Metalloproteases and Use Thereof |
| US9782457B2 (en) * | 2011-10-07 | 2017-10-10 | Tissue Repair Company | Flowable formulations for tissue repair and regeneration |
| WO2015073538A2 (en) * | 2013-11-12 | 2015-05-21 | Echogen, Inc. | Interaction with metalloenzymes |
| CN104710525B (en) * | 2015-03-18 | 2020-08-04 | 浙江海洋学院 | Tuna bone collagen source zinc chelated collagen peptide and preparation method and application thereof |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622871A (en) | 1987-04-27 | 1997-04-22 | Unilever Patent Holdings B.V. | Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents |
| CS249311B1 (en) | 1983-09-29 | 1987-03-12 | Jaroslava Turkova | Proteolytic wound dressing |
| US4882760A (en) * | 1983-12-02 | 1989-11-21 | Yee Raymond M | Sound reproduction system |
| GB2150833B (en) * | 1983-12-08 | 1987-04-15 | Ceskoslovenska Akademie Ved | Proteolytic wounds dressing |
| US4999285A (en) | 1984-11-15 | 1991-03-12 | Syntex (U.S.A.) Inc. | Chromatographic cassette |
| US4868108A (en) | 1985-12-12 | 1989-09-19 | Hygeia Sciences, Incorporated | Multiple-antibody detection of antigen |
| DE3606265A1 (en) * | 1986-02-27 | 1987-09-03 | Roehm Pharma Gmbh | POLYSACCHARID-BASED Wound Dressing As a Carrier Therapeutically Effective, Non-Immobilized Enzymes and with High Absorbency |
| US5112608A (en) * | 1987-03-13 | 1992-05-12 | Incyte Pharmaceuticals | Use of protease nexin-I to mediate wound healing |
| US5196196A (en) * | 1986-06-03 | 1993-03-23 | Incyte Pharmaceuticals, Inc. | Use of protease nexin-I in wound dressings |
| JP2609858B2 (en) | 1987-02-27 | 1997-05-14 | 富士薬品工業 株式会社 | Enzyme immunoassay for collagenase inhibitors |
| DE3856542T2 (en) | 1987-04-27 | 2003-10-30 | Inverness Medical Switzerland | Test device for carrying out specific binding tests |
| CA1313616C (en) | 1987-06-01 | 1993-02-16 | Robert B. Sargeant | Lateral flow, non-bibulous membrane protocols |
| US4943522A (en) | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
| US4956302A (en) | 1987-09-11 | 1990-09-11 | Abbott Laboratories | Lateral flow chromatographic binding assay device |
| EP0306772B1 (en) | 1987-09-11 | 1993-03-10 | Abbott Laboratories | Lateral flow chromatographic binding assay device |
| DK158336C (en) * | 1987-09-22 | 1990-10-01 | Coloplast As | CONNECTOR MATERIALS FOR THE TREATMENT OF WOUNDS AND TEMPLES FOR USE IN MANUFACTURING THEREOF |
| US4876332A (en) * | 1987-10-08 | 1989-10-24 | Regents Of The Univeristy Of Minnesota | Polypeptides with type IV collagen activity |
| US5275785A (en) | 1987-10-30 | 1994-01-04 | Unilever Patent Holdings B.V. | Test device for detecting an analyte in a liquid sample |
| US5670381A (en) | 1988-01-29 | 1997-09-23 | Abbott Laboratories | Devices for performing ion-capture binding assays |
| US5270447A (en) * | 1988-05-20 | 1993-12-14 | The United States Of America As Represented By The Department Of Health & Human Services | Metalloproteinase peptides: role in diagnosis and therapy |
| US5280106A (en) | 1988-05-20 | 1994-01-18 | Liotta Lance A | Matrix metalloproteinase peptides: role in diagnosis and therapy |
| US4883760A (en) | 1988-06-20 | 1989-11-28 | Adi Diagnostics Inc. | Device for performing enzyme immunoassays |
| US5037735A (en) | 1988-06-24 | 1991-08-06 | Microgenics Corporation | Visual discrimination qualitative enzyme complementation assay |
| AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| US5188938A (en) | 1988-12-29 | 1993-02-23 | Microgenics Corporation | Enzyme quantitation wicking assay |
| DK0460016T3 (en) | 1989-02-27 | 1994-04-25 | Univ Texas | Metastasis associated collagenolytic metalloproteinases |
| US5698671A (en) | 1989-03-21 | 1997-12-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Metalloproteinase peptides |
| AU634533B2 (en) * | 1989-03-21 | 1993-02-25 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Matrix metalloproteinase inhibitor peptides |
| JPH02304365A (en) | 1989-05-18 | 1990-12-18 | Shionogi & Co Ltd | Method for measuring elastase i |
| NO177716C (en) | 1989-06-09 | 1995-11-08 | Zeneca Ltd | Method for Preparation of Therapeutically Active Polypeptides, DNA Sequence, Expression Vector and Antibody |
| US5252496A (en) | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
| CZ277766B6 (en) | 1990-01-04 | 1993-04-14 | Vnii Textilno | Biologically active material and process for preparing thereof |
| CA2074507A1 (en) | 1990-01-26 | 1991-07-27 | William G. Stetler-Stevenson | Method for quantitatively measuring collagenase |
| US5141850A (en) | 1990-02-07 | 1992-08-25 | Hygeia Sciences, Inc. | Porous strip form assay device method |
| US5270168A (en) | 1990-02-21 | 1993-12-14 | Board Of Regents, The University Of Texas System | Method for diagnosing non-healing ulcers |
| US5169754A (en) * | 1990-10-31 | 1992-12-08 | Coulter Corporation | Biodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making same |
| JP3081638B2 (en) | 1990-11-16 | 2000-08-28 | 富士薬品工業株式会社 | Monoclonal antibody against human 72 kDa gelatinase and use thereof |
| GB2250993B (en) * | 1990-11-21 | 1995-02-15 | Inst Nat Sante Rech Med | Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer |
| US5484726A (en) * | 1990-11-21 | 1996-01-16 | Bristol-Myers Squibb Company | Antibodies specific for human stromelysin-3 and a method for detection of stromelysin-3 |
| WO1992012428A1 (en) | 1991-01-11 | 1992-07-23 | Quidel Corporation | A one-step lateral flow nonbibulous assay |
| JPH085920B2 (en) * | 1991-01-21 | 1996-01-24 | 富士薬品工業株式会社 | Anti-human stromlysin monoclonal antibody and enzyme immunoassay |
| JP3118015B2 (en) | 1991-05-17 | 2000-12-18 | アークレイ株式会社 | Biosensor and separation and quantification method using the same |
| FR2678513B1 (en) * | 1991-07-03 | 1995-06-30 | Laboratoires Hygiene Dietetique | HEALING DRESSING. |
| JP3076640B2 (en) | 1991-07-26 | 2000-08-14 | 富士薬品工業株式会社 | Immunoassay for human 92kDa gelatinase |
| US5804213A (en) * | 1991-10-09 | 1998-09-08 | Lectec Corporation | Biologically active aqueous gel wound dressing |
| JP3135959B2 (en) | 1991-12-12 | 2001-02-19 | アークレイ株式会社 | Biosensor and separation and quantification method using the same |
| JP3017591B2 (en) | 1992-01-17 | 2000-03-13 | 富士薬品工業株式会社 | Production method of anti-human TIMP-2 monoclonal antibody and use thereof |
| US5541069A (en) | 1992-02-28 | 1996-07-30 | Quidel Corporation | Assay having improved dose response curve |
| WO1993018398A1 (en) | 1992-03-10 | 1993-09-16 | Quidel Corporation | Red blood cell separation means for specific binding assays |
| US5324634A (en) | 1992-03-31 | 1994-06-28 | The Research Foundation Of State University Of New York | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer |
| US5516891A (en) * | 1992-06-16 | 1996-05-14 | Kinerton, Ltd. | Liquid phase synthesis of peptides and peptide derivatives |
| DK88293A (en) | 1992-08-03 | 1994-02-04 | Becton Dickinson Co | Solid Phase Analysis |
| US5734014A (en) | 1992-08-11 | 1998-03-31 | Tsumura & Co. | Elafin derivative |
| US5354692A (en) | 1992-09-08 | 1994-10-11 | Pacific Biotech, Inc. | Analyte detection device including a hydrophobic barrier for improved fluid flow |
| JP3098640B2 (en) | 1992-12-24 | 2000-10-16 | 富士薬品工業株式会社 | Immunoassay for human 72-kDa gelatinase / type IV collagenase |
| JP2673929B2 (en) | 1993-04-12 | 1997-11-05 | 富士薬品工業株式会社 | Immunological assay of human interstitial collagenase-inhibitor complex and its application to clinical diagnosis |
| IT1270951B (en) | 1993-06-07 | 1997-05-26 | Boehringer Mannheim Italia | METHOD AND DEVICE FOR SIMULTAN DETECTION OF NEISSERIA GONORRHOEAE, CHLAMYDIA TRACHOMATIS AND MYCOPLASMA |
| US5415994A (en) | 1993-08-02 | 1995-05-16 | Quidel Corporation | Lateral flow medical diagnostic assay device with sample extraction means |
| JPH07159402A (en) | 1993-12-09 | 1995-06-23 | Kyodo Nyugyo Kk | Iv type collagenase measuring method |
| GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
| US5641636A (en) | 1994-05-20 | 1997-06-24 | University Of Pennsylvania | Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity |
| GB9414303D0 (en) * | 1994-07-15 | 1994-09-07 | C V Lab Ltd | Alginate fibres, method of preparation and use |
| AU3276895A (en) | 1994-07-28 | 1996-02-22 | Pall Corporation | Fibrous web and process of preparing same |
| FI98961C (en) | 1994-08-26 | 1997-09-10 | Medix Biochemica Ab Oy | Procedure and test means for diagnosing periodontal disease activity and / or peri-implantitis and / or increased risk thereof |
| US5605809A (en) * | 1994-10-28 | 1997-02-25 | Oncoimmunin, Inc. | Compositions for the detection of proteases in biological samples and methods of use thereof |
| JPH08136548A (en) | 1994-11-11 | 1996-05-31 | Morinaga & Co Ltd | Diagnostic method for urinary organ cancer |
| US5916521A (en) | 1995-01-04 | 1999-06-29 | Spectral Diagnostics, Inc. | Lateral flow filter devices for separation of body fluids from particulate materials |
| JP2742886B2 (en) | 1995-01-20 | 1998-04-22 | 富士薬品工業株式会社 | Immunoassay for neutrophil collagenase |
| US5569608A (en) | 1995-01-30 | 1996-10-29 | Bayer Corporation | Quantitative detection of analytes on immunochromatographic strips |
| JP2949467B2 (en) | 1995-02-16 | 1999-09-13 | 富士薬品工業株式会社 | Determination of human promatrix metalloprotease 7 by immunoassay |
| JP2864219B2 (en) | 1995-02-20 | 1999-03-03 | 富士薬品工業株式会社 | Fractional determination of free active matrix metalloproteases |
| US5712172A (en) | 1995-05-18 | 1998-01-27 | Wyntek Diagnostics, Inc. | One step immunochromatographic device and method of use |
| US5830468A (en) * | 1995-05-17 | 1998-11-03 | The New York Blood Center, Inc. | Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase |
| US6020181A (en) * | 1995-05-17 | 2000-02-01 | New York Blood, Inc. | Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase |
| US5770691A (en) | 1995-06-05 | 1998-06-23 | Regents Of The University Of Minnesota | Discriminatory substrates for MMP hydrolysis |
| US5935796A (en) * | 1995-06-30 | 1999-08-10 | The University Of Melbourne | Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown |
| EP0870826A4 (en) * | 1995-07-14 | 2002-05-02 | Daiichi Fine Chem Co Ltd | Novel protein and monoclonal antibody specific thereto |
| JPH0987299A (en) | 1995-07-14 | 1997-03-31 | Fuji Yakuhin Kogyo Kk | Monoclonal antibody specific to mmp-2 activation factor |
| IT1277904B1 (en) | 1995-08-07 | 1997-11-12 | Polifarma Spa | METHOD FOR DETERMINING THE THERAPEUTIC ACTIVITY OF METALLOPROTEINASE INHIBITOR COMPOUNDS, NEW INHIBITOR COMPOUNDS, AND THEIR USE |
| US5952236A (en) | 1995-10-26 | 1999-09-14 | Thompson; Richard B. | Enzyme-based fluorescence biosensor for chemical analysis |
| US5741659A (en) | 1996-01-04 | 1998-04-21 | The United States Of America As Represented By The Secretary Of The Navy | Rapid microbial protease assay |
| JP2000503533A (en) | 1996-01-04 | 2000-03-28 | ネーデルランドセ・オルガニザテイエ・フール・テゲパスト―ナトウールベテンシヤツペリーク・オンデルツエク・テイエヌオー | Assay method for protease using fluorescent quenching substrate |
| JPH09206099A (en) | 1996-01-31 | 1997-08-12 | Sekisui Chem Co Ltd | Cell function assay |
| DE69721507T2 (en) | 1996-02-29 | 2004-03-25 | Fuji Photo Film Co., Ltd., Minami-Ashigara | PROCESS FOR ANALYZING PROTEASES AND THIN MEMBRANE FOR USE IN THIS METHOD |
| US5876944A (en) | 1996-06-10 | 1999-03-02 | Bayer Corporation | Method for amplification of the response signal in a sandwich immunoassay |
| US6022948A (en) * | 1996-09-17 | 2000-02-08 | Washington University | Method of cell surface activation and inhibition |
| US5798273A (en) | 1996-09-25 | 1998-08-25 | Becton Dickinson And Company | Direct read lateral flow assay for small analytes |
| DE69732131T2 (en) | 1996-10-25 | 2005-12-15 | Idexx Laboratories, Inc. | Immuno-assay device with divisible housing |
| US5710005A (en) | 1996-10-29 | 1998-01-20 | Biocode, Inc. | Analyte detection with a gradient lateral flow device |
| US6194221B1 (en) | 1996-11-19 | 2001-02-27 | Wyntek Diagnostics, Inc. | Hybrid one-step immunochromatographic device and method of use |
| US6025150A (en) * | 1996-11-21 | 2000-02-15 | The Regents Of The University Of Michigan | Methods and compositions for wound healing |
| US5922550A (en) | 1996-12-18 | 1999-07-13 | Kimberly-Clark Worldwide, Inc. | Biosensing devices which produce diffraction images |
| DE19701141C1 (en) * | 1997-01-16 | 1998-04-09 | Hoechst Ag | Gene construct for treatment of disease involving protease, particularly tumours and inflammation |
| US5879951A (en) | 1997-01-29 | 1999-03-09 | Smithkline Diagnostics, Inc. | Opposable-element assay device employing unidirectional flow |
| GB2322192B (en) | 1997-02-14 | 2001-01-31 | Unilever Plc | Assay devices |
| US6037137A (en) * | 1997-02-20 | 2000-03-14 | Oncoimmunin, Inc. | Fluorogenic peptides for the detection of protease activity |
| US6294344B1 (en) | 1997-03-19 | 2001-09-25 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian cancer |
| US6180288B1 (en) | 1997-03-21 | 2001-01-30 | Kimberly-Clark Worldwide, Inc. | Gel sensors and method of use thereof |
| JPH10287700A (en) | 1997-04-10 | 1998-10-27 | Fuji Yakuhin Kogyo Kk | Antibody against active type matrilysin (mmp-7) and immunoassay using the same |
| JPH10313896A (en) | 1997-05-15 | 1998-12-02 | Yamanouchi Pharmaceut Co Ltd | New synthetic substrate for measurement of activity having chromophore of fluorophore to matrix metalloprotease |
| US6258548B1 (en) | 1997-06-05 | 2001-07-10 | A-Fem Medical Corporation | Single or multiple analyte semi-quantitative/quantitative rapid diagnostic lateral flow test system for large molecules |
| US5895765A (en) | 1997-06-30 | 1999-04-20 | Bayer Corporation | Method for the detection of an analyte by immunochromatography |
| US5985675A (en) | 1997-12-31 | 1999-11-16 | Charm Sciences, Inc. | Test device for detection of an analyte |
| US5876332A (en) * | 1997-07-24 | 1999-03-02 | Genzyme Corporation | Surgical support member |
| US6043087A (en) * | 1997-07-25 | 2000-03-28 | The New York Blood Center | Monospecific antibody reactive with matrix metalloproteinase cleavage products of fibrin(ogen) |
| JPH1183858A (en) | 1997-09-12 | 1999-03-26 | Oriental Yeast Co Ltd | Mmp-9 related new tumor specific antigen |
| US6060256A (en) | 1997-12-16 | 2000-05-09 | Kimberly-Clark Worldwide, Inc. | Optical diffraction biosensor |
| JPH11318449A (en) | 1998-03-10 | 1999-11-24 | Fuji Chem Ind Ltd | Antibody against stromelysin-2 (mmp-10) |
| FI980604A0 (en) * | 1998-03-18 | 1998-03-18 | Univ Helsinki Licensing | New matrix metalloprotein inhibitors and regulators |
| US6183972B1 (en) | 1998-07-27 | 2001-02-06 | Bayer Corporation | Method for the determination of analyte concentration in a lateral flow sandwich immunoassay exhibiting high-dose hook effect |
| US6143506A (en) | 1998-08-13 | 2000-11-07 | The Research Foundation Of State Of Ny | Diagnostic method for detection of periodontitis or peri-implantitis |
| US6136610A (en) | 1998-11-23 | 2000-10-24 | Praxsys Biosystems, Inc. | Method and apparatus for performing a lateral flow assay |
| US6203757B1 (en) | 1998-12-02 | 2001-03-20 | Bionike, Inc. | Fluid sample distriution system for test device |
| US6221579B1 (en) | 1998-12-11 | 2001-04-24 | Kimberly-Clark Worldwide, Inc. | Patterned binding of functionalized microspheres for optical diffraction-based biosensors |
| US6297020B1 (en) | 1999-03-01 | 2001-10-02 | Bayer Corporation | Device for carrying out lateral-flow assays involving more than one analyte |
-
2000
- 2000-12-29 US US09/753,139 patent/US7041787B2/en not_active Expired - Lifetime
-
2001
- 2001-12-21 MX MXPA03005903A patent/MXPA03005903A/en active IP Right Grant
- 2001-12-21 EP EP01991359A patent/EP1348024B1/en not_active Expired - Lifetime
- 2001-12-21 CA CA002431853A patent/CA2431853A1/en not_active Withdrawn
- 2001-12-21 AT AT01991359T patent/ATE342352T1/en not_active IP Right Cessation
- 2001-12-21 WO PCT/US2001/049276 patent/WO2002053173A2/en active IP Right Grant
- 2001-12-21 KR KR1020037008713A patent/KR100818874B1/en active IP Right Grant
- 2001-12-21 AU AU2002231087A patent/AU2002231087A1/en not_active Abandoned
- 2001-12-21 DE DE60123833T patent/DE60123833T2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002231087A1 (en) | 2002-07-16 |
| MXPA03005903A (en) | 2003-09-10 |
| KR20030064885A (en) | 2003-08-02 |
| EP1348024A2 (en) | 2003-10-01 |
| US7041787B2 (en) | 2006-05-09 |
| WO2002053173A2 (en) | 2002-07-11 |
| KR100818874B1 (en) | 2008-04-01 |
| DE60123833T2 (en) | 2007-11-29 |
| ATE342352T1 (en) | 2006-11-15 |
| EP1348024B1 (en) | 2006-10-11 |
| DE60123833D1 (en) | 2006-11-23 |
| US20030073808A1 (en) | 2003-04-17 |
| WO2002053173A3 (en) | 2003-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hersh et al. | Comparison of the subsite specificity of the mammalian neutral endopeptidase 24.11 (enkephalinase) to the bacterial neutral endopeptidase thermolysin. | |
| US6906036B2 (en) | Anti-aging and wound healing compounds | |
| Bieth | Elastases: catalytic and biological properties | |
| CA2125037C (en) | Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality | |
| US4829052A (en) | Serine protease inhibitors | |
| Bjarnason et al. | Proteolytic specificity and cobalt exchange of hemorrhagic toxin e, a zinc protease isolated from the venom of the western diamondback rattlesnake (Crotalus atrox) | |
| AU604944B2 (en) | Cysteine proteinase inhibitor | |
| Maciewicz et al. | Collagenolytic cathepsins of rabbit spleen: a kinetic analysis of collagen degradation and inhibition by chicken cystatin | |
| EP1348024B1 (en) | Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases | |
| AU2003294359A1 (en) | Wound care compositions | |
| US7795225B2 (en) | Anti-chrondrosarcoma compounds | |
| US7186693B2 (en) | Metalloproteinase inhibitors for wound healing | |
| CA2399486A1 (en) | Use of compatible solutes as inhibitors of the enzymatic decomposition of macromolecular biopolymers | |
| US7094754B2 (en) | Anti-aging and wound healing compounds | |
| Lauer-Fields et al. | Analysis of matrix metalloproteinase triple-helical peptidase activity with substrates incorporating fluorogenic L-or D-amino acids | |
| AU2003294360B2 (en) | Method to increase fibronectin | |
| Straight et al. | Structural and functional characterization of the inhibition of urokinase by. alpha. 2-macroglobulin | |
| WO2002053172A2 (en) | Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover | |
| Jacobsen et al. | Localization of. epsilon.-lysyl-. gamma.-glutamyl cross-links in. alpha. 2-macroglobulin-plasmin complex | |
| Roche et al. | Characterization of. alpha. 2-macroglobulin-plasmin complexes: complete subunit cleavage alters receptor recognition in vivo and in vitro | |
| Vettakkorumakankav et al. | Ca2+ and Zn2+ binding properties of peptide substrates of vertebrate collagenase, MMP-1 | |
| Jeng et al. | Mouse macrophage metalloelastase expressed in bacteria absolutely requires zinc for activity | |
| Vijayaragahaven et al. | Reaction of neprilysin (neutral endopeptidase) and thermolysin with cyclic peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| AZWI | Withdrawn application |